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Defective in Cullin Neddylation 1 Domain Containing 1 (DCUN1D1) is an E3 ligase for the post 
translational process, neddylation. Neddylation is similar and runs in parallel to the ubiquitin 
proteasome pathway. Although established as an oncogene in various squamous cell carcinomas, the 
role of DCUN1D1 in prostate cancer has not been explored and it could be a novel drug target for 
prostate cancer treatment. We investigated the role of DCUN1D1 in prostate cancer. The expression 
of DCUN1D1was evaluated in prostate cancer cell lines and human tissue samples and its effect on 
tumourigenesis was tested using proliferation, migration, apoptosis and in vivo tumour growth assays. 
Microarray analysis and the connectivity map database were used to determine the signalling 
pathways responsible for its mechanism of action and to identify compounds specific for DCUN1D1 
to inhibit prostate cancer growth. DCUN1D1 expression was upregulated in multiple prostate cancer 
cell lines, particularly androgen independent prostate cancer cells. Its expression was also upregulated 
by 42% in separate cohorts of human tissue samples. Blockage of DCUN1D1 expression led to a 
significant reduction in proliferation and migration of prostate cancer cells and significantly, it 
inhibited xenograft formation in MF1 nude mice. Microarray analysis identified deregulation of key 
gene expression, cellular growth and proliferation, developmental, cell death and cancer pathways as 
the possible mechanisms by which DCUN1D1 mediates its activated. We tested 30 drugs identified 
using the connectivity map database as having gene expression signatures positively correlated with 
DCUN1D1 knockdown. Monensin and podophyllotoxin were demonstrated to inhibit prostate cancer 
proliferation and induce apoptosis in prostate cancer cells through DCUN1D1-dependent activity. 
Therefore, DCUN1D1 plays a critical role in prostate cancer growth through the deregulation of 
crucial cellular pathways. In addition, the connectivity map database was successfully employed to 
identify small molecule inhibitors of DCUN1D1 that reduce prostate cancer growth. This could lead 
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Chapter 1: Introduction 
1.1 Background and Context of Research 
1.1.1 Prostate gland 
The prostate gland is a small gland (3cm long, 4cm wide and 2cm deep) that is situated at the base of 
the bladder, in front of the rectum and surrounds the urethra (Kumar & Majumder, 1995). It is divided 
into the central, transitional, fibromuscular and peripheral zones (Figure 1) (McNeal, 1981); the latter 




The function of the prostate is to secret an alkaline milky fluid that liquefies semen and helps to 
neutralize the acidic conditions of the vaginal tract (Kumar & Majumder, 1995). However, it is the 
ability of the prostate to grow in response to various androgens that helps to explain its propensity for 
tumour development. Maturation of the prostate gland is initiated at puberty where increased secretion 
of testosterone, results in the differentiation of prostate gland cells, among other activities (Gupta et 
al., 1977). The process begins through binding of the luteinising hormone-releasing-hormone (LHRH) 
to the anterior pituitary gland  (Schally et al., 1970). It is the luteinising hormone (LH) secreted by the 
anterior pituitary gland which then targets the Leydig cells of the testes to produce testosterone 
(Neaves, 1975). Testosterone and its metabolite (dihydrotestosterone) are then recognized by 
androgen receptors (ARs) expressed in prostate epithelial cells to promote prostate cell differentiation 
and to mediate the transcription of genes necessary for prostate gland function. As such, the AR and 
its related pathways have been studied extensively, especially their roles in PCa development and 
progression. We describe the AR and its function in detail later in the study and begin by describing 
the current knowledge on PCa. 
Figure 1. Schematic representation of the human prostate gland and zonal distribution. A) 
Diagram showing the prostate gland situated below the bladder, in front of the rectum. B) 
Schematic model of prostate gland zones namely the central, transitional, anterior fibromuscular 




1.1.2 Prostate cancer 
Prostate cancer (PCa) is the second leading cause of cancer related deaths in the world (Globocan 
2008) and according to the South African National Cancer registry 2004 it is the most common cancer 
in South African males.  In the United States of America, where cancer surveillance is rigorously 
undertaken, an estimated 233000 new cases of PCa will be diagnosed in 2014 and 29480 deaths will 
occur from it in the same period (Siegel et al., 2014). The incidence is highest in men over the age of 
60 years but can occur in men younger than this age (Wingo et al., 1998; Siegel, 2013; Siegel et al., 
2014). Risk factors associated with PCa development include age, family history of PCa, race, 
hormones, oxidative stress, dietary intake, environmental agents and occupation (Meikle et al., 1985; 
Steinberg et al., 1990; Giovannucci et al., 1993; Lesko et al., 1996; Giovannucci et al., 1998; Wingo 
et al., 1998; Sharma-Wagner et al., 2000; Merrill & Morris, 2002; Chen et al., 2003; Wu et al., 2009). 
Many of these risk factors have been identified due to a direct correlation with PCa development or 
because of their protective ability, in that a low level of these factors increases PCa risk. However, 
some of the data around these risk factors, such as occupation, are inconsistent. In addition, risk 
factors such as race where African American men show a high incidence and mortality rate (Jemal et 
al., 2009; Siegel, 2013), could be affected by other aspects such as access to healthcare, attitude to 
seeking medical advice and following up on appointments which include digital rectal examinations 
(Merrill & Morris, 2002). If PCa is suspected, the symptoms associated with it are difficulty urinating, 
pain with ejaculation, blood or semen in the urine and back pain. 
In the next sections, we will discuss the classification/staging of PCa, the various methods used to 
screen for PCa with a brief summary of the current biomarkers used in PCa diagnosis. We will also 
discuss the treatments options that are available, with an in depth analysis of chemotherapy and 
androgen deprivation therapy because we identify our protein of interest, DCUN1D1, as a novel target 
which could be used as an alternative to these types of treatment. We also review the signalling 
pathways that have been associated with PCa development and progression focusing mainly on the 
ubiquitination and neddylation pathways and the two drugs that have emerged as chemotherapeutics 
agent through mechanisms of action dependent on these pathways. We then summarize current 
literature on DCUN1D1 and its link to ubiquitination and neddylation. Lastly, we explore gene 
expression profiles as bioinformatics tools to drug discovery in order to understand the context of this 






1.1.3 Prostate cancer staging 
Prostate cancer staging involves evaluation of the extent of spread of the disease and prediction of 
patient prognosis. It consists of clinical and pathological staging which require analysis of clinical 
findings such PSA levels, digital rectal examinations, imaging as well as pathological analysis of 
tissue samples using the Gleason score (Gleason, 1974; Edge et al., 2010). The Gleason score is used 
to grade the tumour based on the level of differentiation of the cells, with well differentiated cells 
having a low grade and poorly differentiated tumours having a high grade and being aggressive 
(Gleason, 1992). It provides a score for each tumour sample based on the sum of the grades of the 
most prominent (primary) and second most prominent (secondary) tumour grades and ranges between 
2 and 10 (Gleason, 1992). These grades are then used in PCa diagnosis and staging. In addition to 
grading, PCa can also broadly be classified as localized, locally advanced and metastatic but 
pathological staging provides distinct classifications by applying the TNM system. 
The currently used TNM system was developed by the American Joint Committee on Cancer and the 
International Union Against Cancer and describes the extent of the primary tumour (T), the 
involvement of the lymph nodes (N) and the presence of distant metastatic disease (M) (Edge et al., 
2010). The extent of the tumour is divided into the T1, T2, T3 and T4 stages and each of these 
classifications has a further subclassification denoted as a, b or c (Figure 2). These classifications 
describe the spread of the tumour within the prostate gland, extension into the prostatic capsule, 
seminal vesicles and surrounding organs such as the rectum or the bladder.  The N classification then 
describes the involvement of the lymph nodes in terms of presence/absence of nodal invasion. The M 
classification describes surrounding and distant organ involvement including the lymph nodes, bone 
or other sites. These descriptions also assist in assessing the risk of each patient for cancer 
progression. In this regard, descriptions of tumour localization, T1-T4 pathological staging, Gleason 
score analysis and pathological analysis of tumour cores occur. This allows for grouping of patients 
into very low risk, low risk, intermediate risk, high risk and very high risk  (Edge et al., 2010). 
However, prior to the establishment of the stage of the disease, initial prostate cancer diagnosis is 
required which involves testing for known biomarkers of PCa, digital rectal examinations and prostate 
tissue biopsy. The prostate specific antigen (PSA) is the most widely used biomarker for PCa 
development however inefficiencies in its use are leading to increased research into alternative 
molecules to track PCa growth. The following section discusses PSA and the main points in the 






1.1.4 Detection and diagnosis of prostate cancer 
Establishing the presence of PCa in an individual can be achieved through various assessments but it 
is complicated mainly by the architecture and positioning of the prostate gland. As described 
previously, the prostate gland is a small gland that is situated among large organs in the male lower 
abdomen. This makes it difficult to access and difficult to treat. Currently, PCa detection is performed 
by testing for serum prostate-specific antigen (PSA) levels, digital rectal examinations and where 
indicated prostate biopsies (Edge et al., 2010). Each of these tests is useful in trying to determine the 
presence or absence of PCa, however a combination of these tests is recommended for accurate 
diagnosis. 
The prostate specific antigen (PSA) and biomarkers in prostate cancer 
Minimally invasive tests are done on urine and blood samples to detect molecules that are 
differentially expressed in the body due to the development of PCa. Theoretically, these tests allow 
one to determine whether an individual has PCa and the stage of the development. Prostatic acid 
Figure 2. Prostate cancer staging. Schematic diagram showing the extent of primary tumour 
growth over different stages according to the TNM system. Stage 1: non-palpable tumour that is 
likely not visible through imaging. Stage IIA: organ-confined tumour that is palpable on digital 
rectal examination and is visible through imaging. Stage IIB: indicates spread of PCa over both 
lobes. Stage III: tumour that has grown into prostatic capsule and describes the involvement of the 
seminal vesicles. Stage IV: indicating the invasion of surrounding organs such as the external 






phosphatase (PAP) was the first molecule to be used as a biomarker for PCa progression and marker 
to response to androgen deprivation therapy in metastatic PCa and since then several molecules have 
been evaluated as PCa biomarkers. Genetic and protein biomarkers have all been investigated 
however PSA, PCA3 and TMPRSS2-ETS have been the most promising. PSA has been the biomarker 
most extensively used to detect, screen and diagnose PCa. As such, PSA testing has evolved to the 
point of analysis of PSA isoforms, PSA density, PSA velocity and age-specific testing of PSA levels 
but this has also been due to the inefficiencies which have been identified in using PSA as a PCa 
biomarker.  We briefly review PSA, PCA3 and TMPRSS2-ETS and their use in PCa detection below. 
PSA is a glycoprotein that is secreted by the epithelial cells of the prostate gland (Papsidero et al., 
1980; Watt et al., 1986). Upon ejaculation semen coagulates and prostatic secretions within the 
semen, PSA in particular, help dissolve the semen to allow for sperm motility (Huggins & Neal, 1942; 
Lee et al., 1989). PSA is a member of the kallikrein-related serine proteases and cleaves the 
semenogelin and fibronectin proteins which are responsible for the coagulation of semen (Syner & 
Moghissi, 1972; Suominen et al., 1974; Watt et al., 1986; Lilja et al., 1987). Other than its basic 
function in prostatic fluid, serum PSA testing has been used for PCa detection. Elevated PSA levels 
were thought to be associated with PCa development (Stamey et al., 1987) because areas of the 
prostate containing the tumour have disruptions in their basement membranes which facilitates 
increased secretion of PSA to the bloodstream (Webber et al., 1995). However, PSA can be elevated 
by different conditions which affect prostate gland homeostasis. Benign prostate hyperplasia (BPH), 
inflammation of the prostate, urinary tract infections, prostatic and non-prostatic trauma 
(catherisation) also increase serum PSA and as such, other modifications have been suggested to 
improve the predictive value of this test (Stamey et al., 1987; Dalton, 1989; Neal et al., 1992; 
Catalona et al., 1998; Ulleryd et al., 1999). The normal PSA cutoff is 4.0ng/ml and evaluation of PSA 
molecular isoforms, PSA density (total PSA/ prostate volume), PSA velocity (rate of change of PSA 
over time) and age-specific reference ranges are also used  to detect PCa (Babaian et al., 1990; 
Benson et al., 1992; Carter et al., 1992; Dalkin et al., 1993; Oesterling et al., 1993; Smith, 1994; Björk 
et al., 1996; Nixon et al., 1997; Catalona et al., 1998; Kalish, 1999; Gann et al., 2002). Although these 
tests assist in improving the use of PSA, the increased frequency in PSA testing is leading to 
overdiagnosis and overtreatment of patients. Therefore, even with value of the serum PSA test and the 
existence of modifications to the test, it is necessary to identify more specific and accurate biomarkers 
of PCa. It is also why many investigators and institutions are calling for serum PSA to stop being used 
as a PCa biomarker.  
PCA3 and TMPRSS2-ETS are two of the many biomarkers being investigated for use as alternatives 
to PSA and they are very promising. PCA3 is  noncoding RNA that is produced only in the prostate 
gland and is highly expressed in >95% PCa biopsies relative to healthy individuals and individuals 
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with BPH (Bussemakers et al., 1999; Hessels et al., 2003). PCA3 as a urine-based diagnostics 
molecule was also more sensitive and specific for detection of PCa than PSA (Hessels et al., 2003; 
van Gils et al., 2007) which could be attributed to the fact that testing for PCA3 involves initial 
massaging of the prostate. TMPRSS2-ETS on the other hand is a gene fusion between the TMPRSS2 
transmembrane protease and one of ETS transcription factors (Tomlins et al., 2005). Chromosomal 
rearrangements in PCa result in the TMPRSS2-ETS fusion but most commonly TMPRSS2-ERG with 
ERG now being an androgen receptor responsive gene. This rearrangement has been reported to be 
essential throughout PCa developed from prostate neoplasia to metastatic and hormone refractory PCa 
(Iljin et al. 2006; Wang et al. 2006; Nam et al. 2007). It is observed in 40-80% of PCa cases, it has 
been suggested as a predictor of prognosis and has recently been investigated as a urine-based 
biomarker for PCa diagnosis (Laxman et al., 2006; Soller et al., 2006; Yoshimoto et al., 2006; Nam et 
al., 2007).  
Therefore, although there have been failures with using PSA for PCa detection, TMPRSS2-ETS 
fusions and PCA3 testing (which involves a digital massage of the prostate) are highly specific 
biomarker tests that are being investigated. However, testing for serum or urine biomarkers alone is 
not efficient for PCa detection at this point.  Digital rectal examination in combination with biomarker 
testing and biopsies is recommended for accurate PCa diagnosis. 
Digital rectal examination (DRE) and Biopsies 
Digital rectal examination involves feeling the prostate gland for nodules, irregularities in the outline 
or anatomy of the prostate as well as gland fixation (Bickley, 2012). Prostate tissue biopsying is the 
sampling of prostate gland tissue for evaluation for malignancies that is performed after either or both 
serum PSA tests and DRE are abnormal. It involves the use of trans-rectal ultrasound-guided needle 
biopsy (TRUS) or the transurethral resection of the prostate (TURP) for tissue sampling in different 
areas of the prostate (Sfakianos et al., 2011; Harvey et al., 2012).  A sextant biopsy involving the 
resection of 6 cores or an extended biopsy scheme using 12 or more cores is used, with additional 
cores obtained when necessary. Pathological analysis of the tissue cores then occurs where a Gleason 
score is awarded to each of the cores and each tissue sample is examined for the presence and 
percentage of its volume that is occupied by cancerous tissue. This then allows for determinations to 
be made on the presence/absence of PCa. Normal PSA levels have been set at 4.0ng/mL and 
measurements above or at this point would likely be followed by DRE and biopsies. However, some 
investigators have argued for these examinations to be performed at PSA levels ranging between 
2.5ng/mL - 4.0ng/mL since they detected PCa in 22-27% of men with PSA levels between these 
ranges (Catalona et al., 2000; Okihara et al., 2001). However, lower PSA cutoff levels have also been 
observed to reduce the usefulness of DRE and have raised concerns of increased number of 
unnecessary biopsies performed and detection of clinically insignificant tumours (Chen et al., 1999). 
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Although, the usefulness of both techniques is undeniable, there are some disadvantages associated 
with each of them including lack of specificity and complications following biopsies.  
Improvements can be made to both techniques such as using experienced examiners to perform both 
techniques and optimizing the number and location of the cores to be taken during the performance of 
biopsies. However, it is the application of all of these techniques including the modifications to the 
serum PSA test that provides more accuracy in PCa diagnosis and improves the predictive value of 
these techniques also in eliminating the possibility of PCa. Ultimately, identifying a new, more 
specific and sensitive biomarker of PCa could also assist in this regard. However, following accurate 
diagnosis of PCa, effective treatment is required and although progress has been made, treatment of 
PCa is still challenging. In the next section we describe the current treatment methods available for 
PCa and as mentioned previously we focus on chemotherapy and androgen deprivation therapy.  
1.1.5 Treatment of prostate cancer 
Despite the high mortality rate reported, it is possible to treat PCa but it is complicated by several 
factors. The architecture and location of the prostate gland makes it difficult to access, tumours within 
a gland can be heterogeneous (as evidenced by a tumour having different grades) and PCa 
development involves multiple stages which include hormone independent growth. In addition, PCa 
tumour growth can be a slow process with individuals likely to die from diseases other than PCa 
(Wingo et al., 1998). As described previously, although the incidence of PCa is high, mortality in 
terms of PCa related deaths is lower than the incidence in some regions but PCa still remains the 
second leading cause of cancer-related deaths globally (Siegel, 2013). Therefore, physicians are often 
faced with the dilemma of balancing patient education and disease treatment. According to the 
American Cancer Society, commencement of treatment usually takes into account the extent of the 
disease (tumour grades and stage), the patient’s age, life-expectancy, co-morbidities, the feelings of 
the patient and doctor as well as whether treatment would be curative. Treatment of PCa can then 
involve: active surveillance (applied in low-intermediate risk patients), radical prostatectomy, 
interstitial prostatic brachytherapy, external beam therapy, cryotherapy, High Intensity Focused 
Ultrasound (HIFU) therapy, androgen deprivation therapy (ADT)/hormonal therapy and 
chemotherapy (Chodak et al., 1994; D’Amico et al., 1998; Blana et al., 2004; Walsh, 2011; Taneja, 
2013; Zamboglou et al., 2013). For the purposes of this project, we will be focusing on ADT and 
chemotherapy. 
Chemotherapeutic agents currently used in PCa treatment are mainly anti-neoplastic agents that kill 
cancer through microtubule inhibition, inhibition of DNA synthesis and function, and target the 
rapidly dividing nature of cancer cells. Docetaxel, estramustine, mitoxantrone are some of the 
chemotherapeutic agents used in the treatment of PCa with the aforementioned mechanisms of 
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activity (Ho et al., 1991; Dahllöf et al., 1993; Díaz & Andreu, 1993). Docetaxel is also the standard 
frontline treatment for metastatic PCa, with patients showing improvements in survival rates, however 
adverse side effects are observed with its use and several clinical trials have occurred to try to 
improve its efficacy (Petrylak et al., 1999; Tannock et al., 2004; de Bono et al., 2010). Nonetheless, 
although anti-neoplastic agents have shown marked usefulness in the treatment of PCa, hormonal or 
ADT has been the primary target for chemical PCa treatment. The basic principle of this approach has 
been the inhibition of androgen induced prostate cell growth, with studies targeting the relationship 
between the androgen and the AR responsible for its signal transduction. This has been a largely 
successful method of PCa treatment but patients undergoing ADT have suffered deregulation in male 
sexual activity and often relapse with androgen-independent tumours. This leads to patients having 
hormone refractory or castration resistant PCa and studies have shown that following the initiation of 
ADT for advanced PCa, clonal selection, AR gene amplification, mutations in AR genes and 
increased sensitivity of AR to androgens due to increased stability and nuclear localization, have led 
to the emergence of androgen-independent tumours (Koivisto et al., 1997; Holzbeierlein et al., 2004; 
Mizokami et al., 2004). Even though no link has been found between AR signalling and our protein of 
interest as yet, AR signalling plays a critical role in PCa and is essential in understanding the context 
of PCa development and progression and current approaches to chemical PCa treatment. Although 
AR signalling is still targeted, protein targets other than direct inhibitors of AR have also been 
investigated for the treatment of PCa. Our view is that targeting alternative proteins and protein 
pathways may be the key to advancing PCa treatment. Protein degradation is one of the pathways that 
have increasingly been identified as a target for anti-cancer therapy. We perform a brief review of the 
signalling pathways that have been identified as playing a key role in PCa in order to demonstrate the 
current understanding of PCa signalling pathways and where protein degradation pathways fit in this 
scheme.  We also perform a detailed description of the ubiquitination and neddylation pathways 
which are involved in protein degradation and to which our protein of interest, DCUN1D1 is linked. 
1.1.6 Prostate cancer signalling pathways 
There are many intricate signalling pathways that are simultaneously active within normal and cancer 
cells. This is the case also in PCa. Although many have been described, some of the pathways 
demonstrated to play a key role in PCa include the AR, NF-κB, PI3K/AKT and MAPK signalling 
pathways. These pathways include some of the key transcription factors regulating prostate cell 
tumourigenesis but also PCa survival pathways. We have chosen to review these pathways not only 
because they play a key role in PCa but also because they encompass the survival pathways or the 
pathways that are linked to DNA or protein synthesis. They are therefore in contrast to the approach 
taken in this study but are the pathways also affected by current approaches to chemical PCa 
treatment. We explore these signalling pathways below. 
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Androgen receptor signalling and prostate cancer 
As mentioned previously, the androgen receptor (AR) plays a key role in PCa due its effect on 
prostate cell growth. It is a steroid hormone receptor of the nuclear receptor family. It recognizes 
testosterone and its metabolite dihydrotestosterone, dimerizes and translocates to the nucleus (Wilson 
& French, 1976). There are four functional domains through which it mediates its activity including 
the N-terminal domain (NTD) with the transcriptional activation function 1 (AF-1) region, the DNA 
binding domain (DBD), the hinge domain with a nuclear localization signal (NLS) and the ligand 
binding domain (LBD) with the transcriptional activation function 2 (AF-2) region (Tilley et al., 
1989; Jenster et al., 1995; Haelens et al., 2007).  Although it remains in an inactive conformation in 
the cytoplasm through Hsp90 binding (Fang et al., 1996), upon ligand binding it dimerizes and 
translocates to the nucleus to mediate transcription of several genes including PSA, NKX3.1, VEGF-
A, GATA 2, Myc, KLF 4, FGF8 , Cdk1, Cdk2, Cdk4, PMEPA1 and TMPRSS2 (Cleutjens et al., 
1996; Joseph et al., 1997; Lu et al., 1997; Gregory et al., 1998; Gregory et al., 2001; Gnanapragasam 
et al., 2002; Böhm et al., 2009; Thomas et al., 2010; Gao et al., 2013). As a result, ARs play a key role 
in various crucial cellular activities including cell proliferation, development, transcription, the cell 
cycle, signal transduction, etc. and disruptions in AR expression and signalling can often lead to 
tumourigenesis. Amplification of AR gene expression has been implicated in PCa. It is observed in 
majority of hormone refractory PCas, with several studies demonstrating that resumption of AR-
dependent activity is a key mechanism of recurrence of PCa following androgen deprivation therapy 
(Koivisto et al., 1997; Linja et al., 2001; Brown et al., 2002). In addition, AR mutations which 
increased AR activity in response to nonadrogenic molecules and to different transcription factors as 
well as the expression of AR splice variants have all been implicated in the role of AR in PCa 
(Newmark et al., 1992; Marcelli et al., 2000; Watson et al., 2010; Harada et al., 2012; Hay & 
McEwan, 2012; Gao et al., 2013; Schultz et al., 2014; Sun et al., 2014). The consequence of all these 
alterations in AR expression is the upregulation of AR signalling pathways which has been correlated 
with PCa development and progression. Therefore, this pathway has extensively been targeting in 
chemical PCa treatment as indicated in the previous section. 
NF-κB signalling in prostate cancer 
Nuclear factor kappa B (NF-κB) is another transcription factor that has been associated with PCa (Suh 
et al., 2002; Jin et al., 2008). The NF-κB family is composed of five members namely p65 (RelA), 
p100/p52, p105/p50, c-Rel and RelB which homo and heterodimerize in order to bind κB enhancer 
sites on specific DNA sequences (Scott et al., 1993; Dobrzanski et al., 1994; Héron et al., 1995; 
Martin & Fresno, 2000; Coope et al., 2002). They are induced in response to a wide spectrum of 
stimuli leading to the activation of canonical (IKK activation, IκB phosphorylation) and non-
canonical NF-κB signalling pathways (Osborn et al., 1989; DiDonato et al., 1997; Xiao & Harhaj, 
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2001; Coope et al., 2002). Some of the downstream target genes of these pathways include the AR, 
IL-6, PSA and TNF-α which have been associated with PCa development and progression  
(Libermann & Baltimore, 1990; Sawyers, 2002; Gupta et al., 2005; Jin et al., 2008). These genes are 
all upregulated in PCa and have been shown to be associated with androgen dependent or androgen 
independent PCa as well as PCa prognosis.  
PI3K/AKT signalling in prostate cancer  
PI3K/AKT are key signal transduction molecules which have been implicated in several crucial 
cellular activities. PI3K has been shown to phosphorylate phosphatidylinositol (4,5) bisphosphate 
(PIP2) into phosphatidylinositol (3,4,5) trisphosphate (PIP3) and this leads to the recruitment and 
activation  of AKT (Carpenter et al., 1993; Franke et al., 1995). PI3K can bind to several different 
receptors including RTKs (receptor tyrosine kinases) and GPCRs (G protein coupled receptors) while 
AKT activates a wide spectrum of proteins including mTOR (Franke et al., 1995; Phillips-Mason et 
al., 2000; Seasholtz et al., 2001; Murga et al., 2002; Hahn-Windgassen et al., 2005; Várnai et al., 
2005). As such, PI3K/AKT plays a role in signal transduction activity related to cell survival, 
proliferation and differentiation. PCa appears to rely heavily on PI3K/AKT activity with the 
PI3K/AKT/mTOR signalling pathway upregulated in PCa primarily due to loss of expression of the 
negative regulator PTEN (Di Cristofano et al., 1998; Liao et al., 2003; Ghosh et al., 2005). As such, 
AKT inhibitors are currently being evaluated in phase II clinical trials for PCa treatment (Chee et al., 
2007). 
 
MAPK signalling and prostate cancer 
The MAPK signalling pathway is one of the most essential signalling pathways in cells with its three 
major endpoints ERK, JNK and p38 MAPK being the effectors of proliferative and cellular stress 
responses (Fuchs et al., 1998; Zhang et al., 2002; Faust et al., 2012). The MAPK pathway is activated 
in PCa but its role in PCa is highlighted because this pathway mediates the activity of several growth 
factors including EGF and TGF-α which are often overexpressed in PCa (Abreu-Martin et al., 1999; 
Gioeli et al., 1999a; Seth et al., 1999; Kinkade et al., 2008). In addition, it has also been implicated in 
early prostate gland development through the upstream activity of FGFR2, a fibroblast growth factor 
receptor and MAPK pathway inducer, which has been linked to prostate gland development during 
embryogenesis (Marker, et al., 2003).  
 
Although there many signalling pathways and transcription factors deregulated in PCa, a lot of their 
activity converges on the above mentioned pathways. Most importantly however, even within these 
pathways which largely promote DNA and protein synthesis; protein degradation is at play. For 
example the transcription factor NF-κB is directly regulated by protein degradation in that its 
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activation relies on IκB phosphorylation, ubiquitination and proteasomal degradation (Chen et al., 
1995).  
Protein degradation is a highly regulated process and it is as essential to regulating normal cellular 
activity as protein synthesis. The ubiquitin-proteasome pathway is one of the pathways that regulate 
protein degradation and it is responsible for majority of the degradation of intracellular proteins (Rock 
et al., 1994). It consists of an enzymatic cascade that conjugates ubiquitin molecules to specific 
protein substrates and a multi-subunit 26S proteasome which degrades the ubiquitin-tagged proteins 
(Figure 3). Protein degradation and the ubiquitin-proteasome pathway have been described; however 
ubiquitin-like molecules and related pathways such as neddylation are not well understood and their 
role in cancer development is still under investigation. Additionally, even though proteasome 
inhibitors such as bortezomib and inhibitors of neddylation such as the neddylation activating enzyme 
inhibitor MLN 4924 have been developed, efficacy can be improved upon and adverse effects are still 
observed (Hideshima et al., 2001; Hideshima et al., 2003; Soucy et al., 2009). We review the 











1.1.7 The role of ubiquitination under physiological and cancer conditions 
The rate of degradation of a protein is a process that is essential to cellular activity. Protein turnover 
rates determine when and at what level a protein is available to perform its function and the ubiquitin-
proteasome pathway plays a crucial role in this aspect. It is a selective protein degradation pathway 
that employs a repeated three step enzymatic cascade to add multiple 8.5 kDa ubiquitin (Ub) 
molecules to specific target proteins, tagging them for degradation by the 26S proteasome (Figure 3). 
The E1 is the first enzyme in the cascade and its function is to activate ubiquitin using ATP 
(Ciechanover et al., 1981; Ciechanover et al., 1982). The ubiquitin activating enzyme (UAE) was the 
only E1 to be characterised initially, however, Uba6 has recently been identified as having ubiquitin 
activating activity (Groettrup et al., 2008). This is in contrast to the second enzyme in the cascade, the 
E2 ubiquitin conjugating enzyme (UBC), where 37 UBCs have been identified in humans which 
Figure 3. Schematic diagram of the ubiquitination, neddylation pathway and the downstream 
26S proteasome. Left: the ubiquitination pathway begins with activation of the ubiquitin (Ub) by 
the E1 or ubiquitin activating enzyme (UAE) using ATP. This is then followed by the transfer of 
Ub from the E1 to the E2 (ubiquitin conjugating enzyme) which transfer Ub to the E3 ligase. The 
E3 ligase then transfers Ub to specific target proteins called substrates. This can occur for several 
cycles resulting in polyubiquitination of substrate proteins which tags the proteins for degradation 
by the 26S proteasome. Right: the neddylation pathway is similar, in that it also begins with the 
activation of NEDD8 in an ATP-dependent manner by an E1 named the neddylation activating 
enzyme (NAE). It is followed by transfer of NEDD8 to the E2 enzyme which transfers NEDD8 to 
the E3 ligase. The E3 ligase then mediates the transfer of NEDD8 to specific substrate proteins. If 
the substrate proteins are the cullin family of the proteins, the substrate with bound NEDD8 can 
then form part of the E3 ligase of the cullin RING ligase family to enhance ubiquitination. (Duncan 





recognize activated ubiquitin and catalyse it’s transfer to specific E3 ligases (Pickart & Rose, 1985; 
Jentsch et al., 1990; Michelle et al., 2009). The E3 ligase is the last enzyme in the cascade and it 
catalyzes the transfer of Ub first to the lysine residue of a specific substrate then to the lysine residue 
of Ub molecules attached to the substrate (Hershko et al., 1986; Reiss et al., 1989; Peng et al., 2003; 
Li et al., 2007). This can be mediated by the E2 enzyme in complex with the E3 ligase or by the E3 
ligase directly (Ciechanover et al., 1980). There are ~617 genes encoding for putative human E3 
ligases that have been identified in humans therefore, even though the increased number of E2s 
relative to the E1s contributes to the specificity of this pathway, E3 ligases are the main specificity 
factors in ubiquitination (Myung et al., 2008). As a result of the large number of E3 ligases and the 
importance of their activity, they have been studied extensively. 
Firstly, this large group of enzymes is classified into three classes based on conserved domains found 
in their core proteins. The HECT (homologous to E6-AP carboxy terminus) domain proteins, the 
RING (Really Interesting New Gene) and the U-box domain proteins (Freemont & Hanson, 1991; 
Beaudenon, 1995; Hatakeyama et al., 2001). Majority of the E3 ligases that have been described thus 
far are the RING finger domain E3 ligases. These enzymes can be further divided into two subclasses 
namely the monomeric simple RING ligases or multi-subunit cullin RING ligase (CRL) complexes. 
Of particular interest to this project are the multi-subunit cullin RING ligases. They consist of a core 
scaffold protein from the cullin family of proteins (cullin 1, 2, 3, 4A, 4B, 5 and 7), a RING finger 
domain-containing protein RBX1/2, a substrate binding protein and an adaptor protein (Skowyra et 
al., 1997; Kamura et al., 1999; Ohta et al., 1999; Seol et al., 1999; Tan et al., 1999; Chen et al., 2001; 
Zheng et al., 2002). The multi-component CRL and the different combinations of proteins that can be 
used in these complexes allow for recognition of a variety of protein substrates with distinct 
specificity. These substrates in turn are implicated in crucial functions in the cell such as cell cycle 
regulation, cell growth, proliferation, intracellular signalling, DNA repair, pro and anti-apoptotic 
signalling and inflammation (Chen et al., 1995; Fang, 2000; Clifford et al., 2001; Fukuchi et al., 
2003). This indicates the importance of ubiquitination in normal cellular activity and why it, together 
with other protein degradation pathways is often deregulated in cancer.  
There is a very close relationship between ubiquitination and cancer development with 
polyubiquitination and subsequent proteasome degradation either leading to the stabilization of 
oncoproteins or destabilization of tumour suppressor proteins. For example, the tumour suppressor 
p53 is heavily regulated by ubiquitination through targeted degradation by the Mdm2 E3 ligase (Fang, 
2000). P53 is normally inactivated in many cancers and dysregulations in Mdm2 expression or 
activity can alter p53 degradation, making ubiquitination a key regulator of p53 and cancer. The 
BRCA1 gene which plays a crucial role in breast cancer development is a ubiquitin E3 ligase which is 
implicated in cell cycle regulation, DNA repair and apoptosis (Thangaraju et al., 2000; Hashizume et 
al., 2001; Greenberg et al., 2006). These are just two examples where ubiquitination plays a role in 
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cancer, either through the regulation of degradation of a tumour suppressor protein or where one of 
the components of the pathway is itself a tumour suppressor protein. This has been illustrated further 
by the role of the 26S proteasome in cancer, which has been identified as a target for cancer treatment 
through the development of proteasome inhibitors.  
The 26S proteasome is responsible for the degradation of ubiquitinated proteins. It is made up of a 
central barrel-shaped 20S proteasome that has a hollow cylinder shape together with 19S regulatory 
particles on either or both ends of the 20S proteasome (Baumeister et al., 1988; Glickman et al., 
1998). Due to importance of the 26S proteasome as demonstrated in its in role in the UPP and the 
functions affected as a result of the degradation of its target protein substrates and its subsequent 
dysregulation in multiple different diseases (including cancer); the 26S proteasome has become a 
unique target for disease treatment. Several inhibitors of the proteasome have been developed over 
time that block degradation of polyubiquitinated proteins and reverse dysregulation of proteins 
observed under disease conditions. Proteasome inhibitors employ a novel mechanism of anti-cancer 
activity. Instead of targeting the inhibition of DNA and protein synthesis to kill cancer cells as done 
by previous chemotherapeutic agents, they target the inhibition of protein degradation and the 
approach has proven quite successful. We briefly describe one the most successful proteasome 
inhibitors bortezomib. Bortezomib (PS-341) (Millenium Pharmaceuticals) is a small molecular weight 
dipeptide boronate which directly inhibits the chymotryptic site of the proteolytic 20S catalytic core 
of the 26S proteasome (Adams et al., 1998; Adams, 2004). It is a stable, potent, selective but 
reversible inhibitor of the 26S proteasome which has been shown to have anti-cancer activity against 
several different cancers including ovarian, PCa and Lewis lung carcinoma (Herrmann et al., 1998; 
Adams et al., 1999; Teicher et al., 1999; Frankel et al., 2000). It has also successfully deterred the 
characteristic uncontrollably growth of tumour cells in multiple myeloma (MM) cancer (Adams, 
2002; Orlowski et al., 2002; Hideshima et al., 2003; Richardson et al., 2003; Singhal et al., 2003).  
However, trials undertaken identified adverse effects such as gastrointestinal symptoms, fatigue, 
thrombocytopenia, and sensory neuropathy in some patients (Orlowski et al., 2002; Singhal et al., 
2003). This indicated that as much as proteasome inhibitors are a very promising class of anti-cancer 
drugs, the knowledge obtained in the success of these drugs should be used in identifying more 








The identification of proteasome inhibitors as viable targets for anti-cancer drugs has further 
emphasized the importance of the ubiquitin-proteasome pathway in cellular activity and the 
inefficiencies observed in their use in the treatment of multiple myeloma cancer has highlighted a 
potential gap in the market. Therefore our view is that ubiquitin-like molecules and related pathways 
such as NEDD8 are potentially new drug targets for cancer treatments. Unlike ubiquitin, ubiquitin-
like molecules have narrower ranges of protein substrates but their substrates are involved in crucial 
cellular activity. Therefore it is likely that if used in anti-cancer activity there is the potential to obtain 
the same effect but through fewer protein targets and perhaps fewer side effects. NEDD8 in particular, 
is also involved in protein degradation due to its link to cullin-mediated ubiquitination but it has more 
specific substrate proteins than the 26S proteasome and therefore could allow for a more specific, 
targeted treatment for PCa, in this instance. 
1.1.8 Neddylation: a description of an emerging pathway in cancer treatment 
 We have highlighted ubiquitin, the ubiquitin-proteasome pathway and their importance in cell 
activity. However, there are several molecules that are similar either in sequence, structure or cascade 
activity to ubiquitin that have also been identified in prokaryotic and eukaryotic cells. These 
molecules are appropriately called ubiquitin-like proteins (UBL) and include: NEDD8, SUMO-1, 
ATG8, ATG12, ISG15, Urm1, Ufm1, FAT10 and FUB1 (Ciechanover et al., 1980; Haas et al., 1987; 
Loeb, 1992; Michiels et al., 1993; Fan et al.,  1996; Matunis et al., 1996; Kamitani, 1997; Mahajan et 
al., 1997; Mizushima, 1998; Mizushima et al., 1998; Furukawa & Mizushima, 2000; Komatsu et al., 
2004). Majority of these molecules conjugate to a wide range of protein substrates and can affect 
different functions in the cell, however the exact function of some of these molecules is not fully 
Figure 4. Schematic representation of the 26S proteasome, the proteolytic 20S component 
of the 26S proteosome and the proteasome inhibitor bortezomib (PS-341). Far left: central 
barrel-shaped 20S proteasome showing the two outer α rings and the two inner β rings. It 
consists of four stacked hollow rings made up of seven distinct subunits. Middle: 26S 
proteosme consisting of the 19S regulatory subunits and the 20S proteasome. Right: the 
structure of bortezomib (PS-341) a small molecular weight dipeptide boronate which directly 





understood as yet. NEDD8 and the neddylation pathway have been described to some extent already 
and like ubiquitination have been associated with cancer. 
NEDD8, neural precursor cell expressed developmentally downregulated 8, is an 81 amino acid, 9kDa 
ubiquitin-like molecule. It is highly conserved in mammals and shows 60% identity to the amino acid 
sequence of ubiquitin (Figure 5) (Kumar & Tomooka, 1992; Kumar & Yoshida, 1993; Kamitani, 
1997). It also undergoes activation and transfer to specific substrate proteins relying on a conserved 
Gly 76 for activation and Lys 48 for substrate recognition (Kamitani, 1997). However,  it has its own 
distinct E1, E2 and E3, it also has a narrower range of target proteins which seem to localize mainly in 
the nucleus, resulting in a distinct expression pattern in the cell (Kamitani, 1997).  The process of 
addition of NEDD8 to specific substrates or the neddylation pathway has a dedicated E1-activating 
enzyme known as the neddylation activating enzyme (NAE), an AppBp1/UBA3 heterodimer (Gong & 
Yeh, 1999). It catalyzes the activation of NEDD8 in an ATP and Mg
2+
-dependent manner and 
transfers it through a transthiolation reaction to one of two E2s, UBC12/UBE2M and UBE2F 
(Liakopoulos et al., 1998; Huang et al., 2009). It has been suggested that neddylation also requires E3 
ligase activity for the final transfer to its target proteins, namely the cullin family of proteins. 
Significantly, our protein of interest DCUN1D1 is one of the few proteins to have been characterised 
as having NEDD8 E3 ligase activity.  
 
 
The neddylation pathway itself runs parallel to the ubiquitination pathway but it functions 
independent of ubiquitination (Figure 3). There are various levels of regulation from the recognition 
of one of the E2s by the E1 NAE, to the subsequent transfer of NEDD8 to its substrate proteins. It 
also undergoes regulation through the activity of two NEDD8 specific cleavage proteins. 
DEN1/NEDP1/SENP8 catalyzes the cleavage of NEDD8 from an immature 81 amino acid 
polypeptide to a 76 amino acid mature product while COP9 signalosome together with DEN1 catalyse 
deneddylation of neddylated cullin molecules (Mendoza et al., 2003; Pintard et al., 2003; Wu et al., 
2003; Xirodimas et al., 2004). However, apart from the components of the neddylation pathway and 
Figure 5. Aligned amino acid sequences of human, mouse and rat NEDD8 and human 
ubiquitin. Alignment shows high sequence similarity among the sequences with the identical 
amino acid typed in bold. The closed triangle shows Gly76 necessary for NEDD8 and ubiquitin 




the functions of each component, very little is known about which proteins actually get neddylated. 
Although several proteins have been identified as undergoing NEDD8 conjugation, many of these 
studies have established only the ability of NEDD8 to interact directly or indirectly with certain 
proteins but they have not explored the consequences of the conjugation. The most extensively 
studied substrates of neddylation to date are the cullin family of proteins mentioned previously as 
components of ubiquitin E3 ligases and these substrates have illustrated the importance of neddylation 
in cellular activity. 
NEDD8 substrates and the importance of neddylation 
Neddylation has been associated with many important cellular proteins. Mass spectrometry, in vitro 
and in vivo neddylation assays have identified firstly, the cullin family of proteins as NEDD8 
substrates but also several CRL components such as ROC1/RBX1, elongin B/C, Skp1 and F-box 
proteins (Jones et al., 2008). Regulators of neddylation, AppBp1/Uba3, UBC12, p120 
CAND1
, 
DCUN1D1, the 19S proteasomal regulatory subunits and proteins unrelated to neddylation such as 
DNA polymerase, RNA polymerase, SMC2 were also found to be substrates of NEDD8 (Jones et al., 
2008). The cullin family of proteins i.e. cullin 1, 2, 3, 4A, 4B and 5 are the most extensively studied 
NEDD8 substrates (Osaka et al., 1998; Kamura et al., 1999; Liakopoulos et al., 1999; Morimoto et al., 
2000; Querido et al., 2001; Pintard et al., 2003; Meyer-Schaller et al., 2009). As mentioned 
previously, cullin proteins form scaffolding molecules in CRL complexes and as such play a key role 
in ubiquitination. They are susceptible to modification by neddylation with the E2 conjugating 
enzymes, UBC12/UBE2M and UBE2F, targeting cullin 1-4 and cullin 5 respectively for NEDD8 
conjugation (Huang et al., 2009). The conjugation then results in conformational changes in CRL 
complexes, converting them from a closed confirmation to a more open confirmation (Duda et al., 
2008). It also allows for optimal binding of ubiquitin within the CRL complex to substrate proteins by 
accelerating E2-E3 interactions, enhancing the ability of the E2 to bind ubiquitin and creating optimal 
spatial conditions for ubiquitin transfer to specific substrates by the E2 (Kawakami et al., 2001; Saha, 
2008). In addition, neddylation accelerates the removal of CAND1 from Cul1-RBX1 (Duda et al., 
2008), which normally inhibits cullin 1 interaction with other components of the E3 and thus 
negatively regulates ubiquitination. Therefore in this instance, neddylation enhances the 
ubiquitination of proteins targeted for degradation by some cullin RING E3 ligases and by extension 
plays a role in the functions regulated by these proteins such as cell cycle regulation, cell 
proliferation, intracellular signalling and apoptotic signalling. 
In addition, studies have occurred which identified EGFR, Mdm2, the tumour suppressor p53, TAp73, 
pVHL, parkin, PINK1, BCA (Breast Cancer Associated) protein and the ribosomal protein L11 as 
substrates of NEDD8 but they also established the downstream effects of these alterations (Stickle et 
al., 2004; Xirodimas et al., 2004; Oved et al., 2006; Watson et al., 2006; Xirodimas et al., 2008; Choo 
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et al., 2012). EGFR neddylation in response to EGF ligand binding led to endosomal/lysosomal 
degradation of EGFR, L11 neddylation results in the protection of L11 from 26S proteasomal 
degradation thus stabilizing its cellular levels. However, functions independent of ubiquitination or 
stabilization of protein levels are also affected by neddylation. For example, pVHL neddylation is 
required for fibronectin assembly, BCA3 neddylation decreases NF-κB dependent transcription 
activation through the recruitment of the SIRT1 deacetylase to NF-κB and parkin-PINK1 neddylation 
deregulates mitochondrial homeostasis (Stickle et al., 2004; Gao et al., 2006; Choo et al., 2012). 
Consequently, it can be concluded that a variety of biological processes including transcription, 
replication, DNA repair, chromatin organization and remodelling, mitochondrial activity and matrix 
organization are affected by neddylation. Therefore, neddylation as a post translational modification 
plays a role in tertiary protein interactions where it’s binding can enhance the protein’s degradation by 
ubiquitination or endosomal/lysosomal degradation. It can also allow for the recruitment of other 
proteins, nuclear localization of proteins and can affect protein assembly. However, this does not 
account for all of the substrates that have been identified by mass spectrometry as NEDD8 substrates. 
Therefore, a lot is still to be uncovered about neddylation, the biological consequences of its addition 
to substrate proteins and its contribution to disease phenotypes including cancer. 
By virtue of the substrates of NEDD8 identified above, and as a result of some studies that have been 
performed already, it has been hypothesized that neddylation could play a key role in cancer 
development and progression. The cullin family of proteins as components of E3 ligases regulate the 
activity of a variety of proteins already associated with cancer development. The DNA replication 
factor Cdt-1, pIκBα, NRF2 stress responsive factor, HIF1α, c-Jun, and the cell proliferation regulator 












respectively and they have all been associated with various cancers (Winston et al., 1999; Clifford et 
al., 2001; Kobayashi et al., 2004; Nateri et al., 2004; Yada et al., 2004; Nishitani et al., 2006). In 
addition, the established NEDD8 substrates EGFR, p53, Mdm2, and pVHL have been reported to play 
a role either in lung cancer, PCa, glioblastoma and renal cell carcinoma (Reifenberger et al., 1993; 
Eastham et al., 1995; Clifford et al., 2001; Zhang et al., 2012). Significantly, an inhibitor of the NAE, 
MLN4924 has been identified which shows anti-cancer activity against colorectal, liver, breast, 
pancreatic, lung cancer cell lines and inhibits tumour xenograft growth in colorectal and lung cancer 
cells (Soucy et al., 2009; Lin et al., 2010; Milhollen et al., 2011; Luo et al., 2012; Toth et al., 2012; 
Wei et al., 2012). It is also currently in a phase 1 trial for use in adult non hematologic malignancies 
by Millenium Pharmaceuticals. As mentioned previously, NEDD8 activation involves the use of ATP 
and during the activation process a NEDD8-AMP acyl adenylate intermediate forms which interacts 
with the active site thiol of the NAE resulting in NEDD8 binding to NAE and AMP being released 
(Gong & Yeh, 1999). MLN4924 is structurally similar to AMP (Figure 6) and it inhibits specifically 
NAE by binding to it instead of AMP. It is also specific to the NAE showing no binding to any other 
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related enzymes such as UAE, SAE (SUMO-1 E1), UBA6 (FAT10 E1) and ATG7 (ATG8 and 
ATG12 E1) or other ATP-using enzymes (Soucy et al., 2009). The anti-cancer activity of MLN4924 
involves the disruption of CRL-mediated protein turnover, leading to the accumulation of several 
CRL substrates including Cdt-1, pIκBα (Lin et al., 2010; Milhollen et al., 2010). This results in cell 
cycle arrest, induction of apoptosis and it also induces autophagy in liver cancer cells. 
 
 
Therefore, the neddylation pathway has not only been identified as important for normal cellular 
activity, it is also essential for cancer development. The identification of the NAE inhibitor MLN4924 
emphasizes both of these points and further illustrates the importance of protein degradation/ 
modification pathways for tumourigenesis. For that reason, we have identified neddylation, in 
particular DCUN1D1 as potentially playing a role in PCa development and we explore the 
characteristics of DCUN1D1 below. 
1.1.9 DCUN1D1 and cancer 
The proteins DCN-1 and Dcn1p were originally described in Caenorhabditis elegans (C. elegans) and 
Saccharomyces cerevisiae (S. cerevisiae) respectively as conserved proteins essential for cullin 
neddylation (Kurz et al., 2005). DCN-1 in particular was identified because defects in embryonic cell 
division of C. elegans due to dcn-1 knockdown were similar to those observed in cells lacking cullin-
3 ligase activity and because DCN-1 mediated post-meiotic degradation of MEI-1, a meiotic 
microtubule degrading protein. Both DCN-1 and Dcn1p have an N-terminal UBA-like domain 
through which they bind ubiquitin with high affinity but they show specificity for NEDD8 that is 
independent of the UBA-like domain (Kurz et al., 2005; Kurz et al., 2008). They also show high 
nuclei expression with lower levels in the cytoplasm, similar to that observed in NEDD8 and COP9 
signalosome. Direct binding to NEDD8, Cdc53 (cullin 1 homologue) and RBX1 as well as similarities 
between defects observed during dcn-1 knockdown and aberrant neddylation observed in C. elegans 
embryos all indicated that DCN-1/Dcn1p played a key role in the neddylation pathway (Kurz et al., 
2005; Yang et al., 2007; Kurz et al., 2008). However, DCN-1 lacks a prototypical RING or HECT 
Figure 6. Structural images of the NAE inhibitor MLN4924 and adenosine 5’ –




domain and Dcn1p overexpression in S. cerevisiae is not able to inhibit Cdc53p deneddylation by 
COP9 signalosome indicating that they cannot initiate neddylation in vitro (Yang et al., 2007; Kurz et 
al., 2008). Nevertheless, they are essential for normal cellular activity because reduced cullin-3 
neddylation in C. elegans and  S. cerevisiae is lethal (Kurz et al., 2005). Similar observations were 
made in the human DCN-1/Dcn1p homologue known as DCUN1D1/SCCRO, we explore these 
observations below.  
Although initially described in humans due to its association with amplifications along 3q26.3 in 
various squamous cell carcinomas, DCUN1D1 is an essential component of the E3 complex of 
neddylation (Sarkaria et al., 2006; Kim et al., 2008). It binds to the core Cul1-RBX1 complex of 
neddylation, the E2 UBC12/UBE2M and the inhibitory CAND1 proteins (Kim et al., 2008). It is 
observed to enhance the kinetics of neddylation by the recruitment of NEDD8-bound 
UBC12/UBE2M and acceleration of CAND1 dissociation from Cul1-RBX1 to promote the formation 
of the neddylation E3 ligase complex. Significantly, DCUN1D1 is crucial for normal cellular activity 
in vivo, in that DCUN1D1 knockdown in mice results in several defects including high rates of 
perinatal mortality, runting and male specific infertility (Huang, Kaufman, Ramanathan, & Singh, 
2011). Part of its importance stems from the fact that DCUN1D1 mediates nuclear localization of 
cullin proteins during in vivo neddylation. The neddylation E2 UBC12/UBE2M is primarily localized 
to the nucleus while cullin 1 proteins are localized mainly in the cytoplasm with those lacking NLS 
not being able to undergo neddylation in vivo. In addition, DCUN1D1 is observed to mediate 
translocation of cullin 1 to the nucleus with DCUN1D1 proteins lacking their NLS not being able to 
promote cullin 1 neddylation in vivo. Therefore, DCUN1D1 does not enhance neddylation but is 
crucial for its progression since it is required in order translocate the Cul1-RBX1 complex into the 
nucleus where majority of the UBC12/UBE2M enzymes are located in order to promote E2-E3 
interactions for NEDD8 transfer to cullin 1; a function that is not necessary in vitro. This activity has 
proven to be essential also for tumourigensis, as DCUN1D1 has been strongly associated with cancer 
phenotypes. 
Positional cloning of the common 3q amplification led to the discovery of DCUN1D1, a homolog of 
DCN-1 and Dcn1p with a propensity for amplification in human cancer cells. DCUN1D1 is also 
known as the squamous cell carcinoma related oncogene (SCCRO) due its prevalence in squamous 
cell carcinomas (SCCs). It is upregulated in head and neck, lung carcinomas and it plays a role in 
gliomas and cervical cancer (Sarkaria et al., 2006; Broderick et al., 2010). Cells overexpressing 
DCUN1D1 were observed to undergo apoptosis upon treatment with DCUN1D1 RNA interference 
and DCUN1D1 overexpression was shown to result in the malignant transformation of NIH-3T3 
fibroblasts and xenograft formation in nude mice (Sarkaria et al., 2010). In addition to promoting 
cancer cell survival by the inhibition of apoptosis, DCUN1D1 increases cell proliferation, and induces 
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metastasis, invasion and angiogenesis through MMP2 and VEGF-A related pathways  (Sarkaria et al., 
2004; O-charoenrat et al., 2008; Broderick et al., 2010). It also binds the promoter of Gli1, a 
component of the hedgehog signalling pathway which is important for embryogenesis and cancer 
(Sarkaria, et al., 2006).  
Therefore, although established as an oncogene in various SCCs, DCUN1D1 is an underexplored 
potential therapeutic target in PCa and it may be a key new candidate for targeted therapy. We 
decided to investigate the importance of DCUN1D1 for PCa, assessing DCUN1D1 expression and 
using molecular biology and genomics approaches to identify DCUN1D1 inhibitors. In particular we 
chose to use the connectivity map database bioinformatics tool, which uses gene expression signatures 
to connect genes, diseases and drugs. 
1.1.10 The use of bioinformatics tools in drug discovery: the connectivity map database 
Since the development of high throughput data generation and analysis, there have been large 
amounts of gene expression profiles, disease gene profiles as well gene expression profiles of drug 
activity in cancer that have been generated. Bioinformatics has played an essential in the analysis of 
this data and in how this data is used in cancer drug discovery. Traditional methods of drug discovery 
employed a structural approach where virtual screening was used to identify protein inhibitors using 
the 3D structure of target proteins (Cheng et al., 2007). However, there are limited 3D structures of 
the multitudes of proteins present in the cell which made this approach difficult. Therefore, 
computational bioinformatics and systematic medicine have emerged as alternative and successful 
approaches. These have been applied extensively in identifying potential protein targets to inhibit PCa 
progression or drug targets in the treatment of PCa (Yi et al., 2009; Yeh et al., 2012; Wen et al., 
2013). Microarray analysis, Drugbank, Gene Ontology (GO) and KEGG pathway are some of tools 
that have been used to generate and analyze large gene expression profiles and to analyze the 
alterations in gene expression that are observed following the use of drugs in disease treatment 
(Kanehisa, 2002; Ashburner et al., 2011; Yeh et al., 2012). However, the large size of these data, the 
complex nature of the profiles revealed and the separation of these sets of data have made it 
challenging to connect them during drug discovery. The connectivity map database was established to 
bring them together. 
The connectivity map (cmap) database was established in 2006 by Lamb et al and is based at the 
Broad Institute of MIT and Harvard in Cambridge, Massachusetts (Lamb et al., 2006). It is a large 
public database that uses genomic signatures to find patterns between physiological, disease, 
chemically-induced or RNA interference-induced biological states. Modern day research has 
established that each of these states is as a result of multiple different signalling pathways within the 
cell, composed of multiple different genes. The link between each of these states is not always 
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understood, which makes drug discovery, disease treatment and basic understanding of molecular 
biology difficult. The cmap database uses a collection of genome-wide transcriptional expression data 
from cultured human cells treated with bioactive small molecules and simple pattern-matching 
algorithms to enable the discovery of functional connections between drugs, genes and diseases 
(Lamb, 2007).  It contains more than 7,000 expression profiles representing 1,309 compounds and has 
the potential of helping researchers identify drugs acting through a common mechanism of action e.g. 
HDAC inhibition, identifying mechanisms of action of specific drugs and identifying compounds for 
potential use in new therapeutic treatments (Lamb et al., 2006). Significantly, some of the compounds 
available on the database are U.S. Food and Drug Administration (FDA) approved drugs which means 
that they are suitable for use in humans. The major appeal of the cmap database is that it allows the 
researcher to input gene signatures generated from mRNA expression following the treatment of 
different cultured cell lines, using DNA microarray analysis on Affymetrix plates. These gene 
signatures are uploaded into the database and comparisons are made between the gene profiles 
generated following the researcher’s experimental conditions and the gene signatures in the database 
in a manner similar to the comparison of gene sequences by Genbank. Therefore the cmap database 
allows for simplified connection of gene expression signatures and drug or drug-like molecules to 
investigate research questions. In this study it is used to identify small molecule inhibitors of PCa that 
mediate their activity through DCUN1D1.  
In summary, the discovery of the PCa biomarker PSA has led to increased detection of PCa, allowing 
for early detection and treatment in some cases of PCa and a subsequent decline in PCa mortality in 
developed countries (Siegel, 2013). However, PSA testing has also resulted in the detection of 
clinically insignificant cancer. In addition, the slow development of PCa means that many individuals 
die with PCa rather than from PCa (Wingo et al., 1998). In spite of this, there is still a heavy PCa 
burden in the world even with advances in the detection and treatment of PCa. Therefore, there is a 
need for effective treatment of all stages of PCa. As a result, we have explored cellular pathways that 
have emerged as effective targets for cancer treatment, namely the ubiquitination and neddylation 
pathway. In particular, we investigate the role of the neddylation E3 ligase DCUN1D1 on PCa 
development and progression and use novel bioinformatics tools to identify potential inhibitors of 
DCUN1D1 for PCa treatment. We have reviewed the ubiquitination, neddylation pathways and 
DCUN1D1 and explore their importance to normal cellular activity, their role in tumourigenesis and 
drugs currently used to target ubiquitination and neddylation. We have highlighted the importance of 
these pathways and our protein of interest DCUN1D1 and demonstrate their viability as targets for 
drug development.  
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1.2 Rationale of the study 
PCa is a highly prevalent disease and although treatment options for patients with early stage PCa are 
high, there are fewer options for individuals with stage III and stage IV disease. The architecture and 
the location of the prostate gland itself contributes largely to difficulty in PCa but the multi-stage 
development, heterogeneous nature of tumours within the same gland, androgen dependence and 
independence of some tumours and the lack of efficient biomarkers; also contribute to the difficulty. 
Crucial to molecular target based PCa treatment is the identification of specific protein targets for 
cancer treatment. We have highlighted the emergence of a novel approach to cancer treatment which 
involves the inhibition of protein degradation in which our protein of interest can potentially play a 
role. Ubiquitination and the neddylation pathway are essential cellular activities to which DCUN1D1 
is linked making it an important cellular protein and potential drug target.  
As illustrated above ubiquitination and neddylation are essential pathways for normal cellular activity 
that can be and are deregulated in cancer. DCUN1D1 is an underexplored oncogene with links to 
essential cellular activity and could be playing a role in PCa development. In addition, the proteasome 
inhibitor bortezomib and the NAE inhibitor MLN4924 have indicated that ubiquitination and 
neddylation are viable emerging targets for anti-cancer therapy but the broad range of proteins 
targeted by these drugs leads to many side effects that could be avoided with more specific drug 
targets within these pathways. We propose that DCUN1D1 could be this target. 
1.3 Aims and Objectives 
Therefore we hypothesize, and aim to establish, that DCUN1D1 may play a role in PCa development 
and could be a potentially new target for PCa treatment. For this reason, we also explore novel 
bioinformatics approaches through the connectivity map database in order to identify DCUN1D1 
specific inhibitors for PCa. 
Specifically, this study has the following aims: 
1) To determine the level of expression of DCUN1D1 in a panel of PCa cell lines and human 
tissue samples. 
2) To determine the relevance of DCUN1D1 for: proliferation, migration and apoptosis of PCa 
cells in vitro and tumour formation in vivo. 
3) Determine signalling pathways in which DCUN1D1 is involved using microarray analysis. 
4) Use the connectivity map database to identify drugs with similar effects as DCUN1D1 




Chapter 2: Materials and Methods 
2.1 Determination of DCUN1D1 expression level in prostate cancer cell lines and human 
tissue 
2.1.1 Cell lines and maintenance of the cells 
Cell lines and culture 
Human PCa cell lines CW22, CW19, LNCaP (CRL-1740), VCaP (CRL-2876), DU145 (HTB-81), 
DUCaP, PC3 (CRL-1435), CL1 and a normal epithelial prostate cell line, PrEC (PCS-440-010) were 
obtained from the American Type Culture Collection (ATCC) (Rockville, MD). CW22, CW19, 
VCap, DU145, DUCap, were grown in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, Life 
Technologies, USA). LNCap and CL1 were grown in Roswell Park Memorial Institute-1640 (RPMI-
1640) medium (Sigma-Aldrich, ST Louis, USA) while PrEC was grown in Prostate Epithelial Cell 
Basal Medium (PreEBM) (Lonza, Walkersville MD, USA). All of the media was supplemented with 
10% fetal bovine serum (FBS) (Biochrom AG, Berlin) and 1% penicillin (5000μg/ml)/streptomycin 
(500μg/ml) (Lonza, Walkersville MD, USA). The cells were incubated at 37°C in a humidified 
atmosphere of 5% CO2 until confluent.  
Seeding and harvesting of tissue culture cells 
All of the cell lines were seeded on tissue culture dishes 100×20mm (BD Falcon, USA). During 
harvesting, the cells were washed in 1×phosphate buffered saline (PBS) pH 7.4 (137mM NaCl, 
2.7mM KCl, 4.3mM Na2HPO4·7H2O, 1.4mM KH2PO4), detached using 0.05% Trypsin/EDTA 
(Gibco, Life Technologies, USA) and incubated under humidified conditions for between 1-10 
minutes depending on the cell line. Trypsin activity was then inhibited through the addition of DMEM 
(Gibco, Life Technologies, USA), RPMI 1640 (Sigma-Aldrich, ST Louis, USA) and PreEBM (Lonza, 
Walkersville MD, USA) containing 10% FBS (Biochrom AG, Berlin) and 1% penicillin 
(5000μg/ml)/streptomycin (500μg/ml) (Lonza, Walkersville MD, USA). The cells were then 
resuspended in the media, combined with 0.4% trypan blue stain (Molecular probes, Life 
Technologies, USA) and quantified using the Countess Automated Cell Counter (Invitrogen, Life 
Technologies, USA). The volume (μl) of cells to be added was calculated as follows:  
       
                    
             






2.1.2 Evaluation of DCUN1D1 expression in human tissue samples 
OriGene TissueScan Prostate Cancer Tissue Array analysis 
Real-time PCR analysis of human tissue samples was performed using the Origene TissueScan 
Prostate Cancer Tissue Array I and II (OriGene Technologies, Rockville, MD, USA) platform. 
According to the manufacturer’s protocol, the samples were evaluated for DCUN1D1 expression and 
normalized against β-actin. The plate consisted of 48 complementary DNAs (cDNAs) namely: 28 
adenocarcinoma of prostate tissue stages I, II and III, 11 benign prostate hyperplasia (BPH), 7 normal 
prostate tissue and 2 bladder carcinoma tissue samples as other disease controls.   
Immunohistochemistry analysis 
Sixteen human tissue samples comprising of paired cancer and normal tissue were evaluated for 
DCUN1D1 expression using immunohistochemistry. The tissue samples were collected and 
pathologically analysed by Dr Yihong Wang at Brown University, USA as prescribed by their ethics 
board. Once the tissue was collected, it was fixed in 10% formalin (2ml per 100mg of tissue) and 
dehydrated using increasing concentrations of ethanol (Merck, Germany). The ethanol was then 
cleared using xylene (2 times  for 1 hour each) and embedded in paraffin (Paraplast X-tra, Sigma-
Aldrich, USA) (2× 1 hour incubations) for preservation. Five micrometre thick sections were then 
sliced from the tissue using a cryostat and mounted onto slides.  Although slicing of the sections 
increased exposure to the epitopes, the paraffin was first cleared using xylene (3 times 5 minutes 
each) and rehydrated in decreasing concentrations of ethanol. Antibody staining then began with heat-
induced antigen retrieval where the slides in 10mM citrate buffer pH 6.0 were boiled at 750W for 10 
minutes and at 305W for 20 minutes in a microwave oven. This allowed for the breakdown of the 
crosslinkages that occur between formalin and tissue proteins in order to increase the probability of 
binding to antibodies. Prior to antibody incubation, the slides were blocked in 1× Tris buffered 
saline/0.1% Tween 20 (Sigma-Aldrich, USA) (TBST) and 5% goat serum (Sigma-Aldrich, USA) for 
1 hour at 23°C. The slides were then incubated in primary antibody, mouse monoclonal anti-
DCUN1D1 (1:200) (Santa Cruz Biotechnology Incorporated) for 16 hours at 4°C in order to probe for 
the antigen. Washing of the slides then occurred in 1×TBST (3 times for 5 minutes). The slides were 
then incubated in biotinylated goat anti-mouse (Sigma-Aldrich, USA) for 30 minutes at 23°C, 
following this; the slides were washed in 1×TBST (3 times for 5 minutes).  Using the avidin/biotin 
method, the slides were incubated in ExtrAvidin-peroxidase/biotin (Sigma-Aldrich, USA) for 30 
minutes at 23°C. The solution was then removed through washing in 1×TBST, 3 times for 5 minutes, 
following which the relevant substrate was added to the slides. The staining was monitored closely 
and once the sections had developed, the slides were immersed in dH2O. Where necessary, the slides 
were counter-stained in hematoxylin. The slides were initially washed twice for 5 minutes in dH2O; 
they were then dehydrated using 95% ethanol (2 times for 10 seconds each) and 100% ethanol (2 
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times for 10 seconds each). The slides were then cleared using xylene (2 times for 10 seconds each) 
following which coverslips were mounted on the slides and viewed.  
2.1.3 Quantitative real time PCR (qRT-PCR) 
Six well tissue culture plates (Cellstar, Greiner Bio-one, Germany) were used to seed 3×10
5 
cells/ 
well. The cells were harvested and counted as described above, incubated and allowed to attach for 16 
hours. Total RNA was extracted using the protocols outlined in RNeasy mini kit (Qiagen, Valencia, 
CA, USA) and using the Qiashredder (Qiagen, Valencia, CA, USA) as previously described (Zerbini 
et al., 2003). When necessary the extracted RNA was stored at -80°C. Prior to use the RNA was 
quantified using the Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific, USA) where 
A260/280 and A260/230 ratios were performed in order to ensure that there was no contamination 
with protein or organic compounds. Complementary DNAs were then generated from 2μg total RNA 
using the Transcriptor First Strand cDNA Synthesis Kit (Roche, Germany). Specifically, 2μg RNA, 
anchored-oligo(dT)18 primer (2.5μM) and PCR grade water were used to generate the cDNA. The 
2720 Thermocycler
 
(Applied Biosystems, Life Technologies, USA) was used to perform the assay. 
An initial denaturation step at 65°C for 10 minutes was performed, followed by the addition of a 
reaction buffer mixture. The mixture contained: 5×Transcriptor Reverse Transcriptase Reaction 
Buffer (8 mM MgCl2), 20U Protector RNase Inhibitor (40U/μl), 1mM Deoxynucleotide Mix (10 mM 
each) and 10U Transcriptor Reverse Transcriptase (20 U/μl).  The last steps of the cDNA synthesis 
were then performed at 25°C for 10 minutes and 50°C for 60 minutes. The Transcriptor Reverse 
Transcriptase was inactivated by incubation at 85°C for 5 minutes and the reaction was stopped by 
incubation at 4°C. The cDNAs were then stored at -20°C until required.  
Quantitative real time PCR (qRT-PCR) was performed as described previously (Zerbini et al., 2003). 
SYBR
® 
fast qPCR master mix (2×) universal (Kapa Biosystems, South Africa), forward and reverse 
primers and molecular grade water (Sigma-Aldrich, Germany) were used to amplify cDNA. The 
SYBR
® 
fast qPCR master mix (2×) universal contained SYBR® Green I fluorescent dye, MgCl2, 
dNTPs, and stabilizers. One microlitre of cDNA in a final volume of 20μl was added to low-profile 96 
well cell culture plates (SPL Life Sciences, Korea). The conditions for PCR were: 1 cycle of 5 
minutes at 94°C; 45 cycles of 30 seconds at 95°C, 1 cycle of 30 seconds at 56°C, and 1 cycle of 30 
seconds at 72°C. Melting curve genotyping: 15 seconds at 95°C, 2 minutes at 65°C, 97°C (continuous 
acquisition, 5 acquisitions per °C) was then performed. For each run, human glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used to normalize each sample and the primers for GAPDH 
were also used to quantify the amount of cDNA in a reference sample. A single point from a human 
GAPDH serial dilution performed previously was used as a reference sample for the absolute 
quantification of the amplified DNA i.e. gene expression based on a standard curve. All of the 
samples were run in triplicate and the final presentation of the data occurred as a ratio of gene of 
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interest to GAPDH. The sequences of the primers used were: DCUN1D1, 5’- 
TCTGTGATGACCTGGCACTC- 3’ (sense) and 5’-GCCATCCATGAACTCCTGTT-3’ (anti-sense) 
(MWG Biotech Incorporated, USA); GAPDH, 5’-GTCTTCACCACCATGGAGAA-3’ (sense) and 
5’-ATCCACAGTCTTCTGGGTGG-3’ (anti-sense) (IDT Technology, USA).  
2.1.4 Western blot analysis 
Cell lysate preparation 
Six well tissue culture plates (Cellstar, Greiner Bio-one, Germany) were used to seed 3×10
5 
cells/ 
well. The cells were harvested and counted as described above, they were then incubated and allowed 
to attach for 16 hours. Following the necessary treatment with drugs or reagents, the total protein was 
extracted using 1×cell lysis buffer [20mM Tris-HCl (pH 7.5), 150mM NaCl, 1mM Na2EDTA, 1mM 
EGTA, 1% Triton-X 100, 2.5mM Na4P2O7, 1mM beta-glycerphosphare, 1mM Na3VO4 and 1μg/ml 
leupeptin]. The cell lysis buffer was supplemented with protease (Roche, Germany) and phosphatase 
inhibitors (Roche, Germany) in order to prevent degradation of the proteins following cell lysis. The 
procedure involved removal of media followed by washing of the cells with 1× PBS pH 7.4, on ice. 
Whole cell lysates were then collected in sterile 1.5ml tubes following scraping of the attached cells 
using cell scrapers (Greiner Bio-one, Germany), on ice. The proteins were then separated from the 
cell debris by centrifugation at 16 000×g for 2 minutes and transferred to sterile 1.5ml tubes. 
Protein quantification 
Prior to use, the protein level in each sample were quantified using the Bradford reagent protein assay, 
involving standard curve preparation and extrapolation of protein concentration from the equation of 
the line. The standard curve was prepared using serial dilutions of bovine serum albumin protein 
solutions 0.5μg/ml, 0.375μg/ml, 0.25μg/ml, 0.1μg/ml and 0.05μg/ml, where 10μl of each was added 
to the wells of an EIA-RIA 96 well plate (Costar, Corning Incorporated, USA). Either 1μl or 0.5μl of 
the cell lysate was then used to determine the concentration of protein in the sample. Since the cell 
lysate is transparent, 200μl of 1× Protein Assay Dye Reagent Concentrate (Bio-Rad, Germany) was 
added to each sample so that Coomassie Brilliant Blue G-250 dye within the concentrate could bind 
the proteins in the samples and the differences in colour changes due to variation in protein 
concentration could be measured based on their absorbance at 595nm. These absorbance readings 
were then used to calculate the volume of protein necessary to load 100μg of the protein. The protein 
was mixed with 1×loading buffer [4× Tris-HCl/SDS pH 6.8, 30% glycerol, 1% SDS, 10% (v/v) β-
mercaptoethanol, 0.012% (w/v) bromophenol blue, dH20] and electrophoresed in a 12% SDS-
polyacrylamide gel consisting of 12% separating gel [Acrylamide/Bis-acrylamide (30%/0.8% w/v) 
(Sigma-Aldrich, USA), 1.5M Tris-HCl pH 8.8, dH20, 10% (w/v) ammonium persulfate (APS), 
N,N,N',N'-Tetramethylethylenediamine (TEMED) (Sigma-Aldrich, USA)] and 3.9% acrylamide 
stacking gel [Acrylamide/Bis-acrylamide (30%/0.8% w/v) (Sigma-Aldrich, USA), 0.5M Tris-HCl pH 
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6.8, dH20, 10% (w/v) ammonium persulfate (APS), N,N,N',N'-Tetramethylethylenediamine (TEMED) 
(Sigma-Aldrich, USA)]. The electrophoreses was performed in 1× running buffer [1% SDS, 0.25M 
Tris pH 8.3, 1.92M glycine and dH2O]. A protein ladder (Precision plus protein
 
prestained standards, 
Biorad, USA) was used to keep track of protein separation. 
Protein electrophoreses, membrane electroblotting and antibodies 
The proteins were electroblotted onto a 0.2μm nitrocellulose membrane (Bio-rad, Germany) using 1× 
transfer buffer [0.25M Tris pH 8.3, 1.92M glycine, 1% methanol (Kimix Chemical Lab Suppliers, 
South Africa) and dH2O]. Following this, the membrane was incubated in 5% fat-free milk (Clover, 
South Africa) dissolved in 1×PBS/0.1%Tween 20 (Sigma-Aldrich, USA) for 1 hour. The membrane 
was then probed using primary anti-bodies dissolved in 5% fat-free milk (Clover, South Africa) and 
1×PBS/0.1%Tween 20 (Sigma-Aldrich, USA) for 16 hours. The membrane was washed with 
1×PBS/0.1%Tween 20 (Sigma-Aldrich, USA) (3 times for 10 minutes, with shaking) to remove 
excess antibodies. It was then incubated with a horseradish peroxidise (HRP) conjugated secondary 
antibody dissolved in 5% fat-free milk (Clover, South Africa) and 1×PBS/0.1%Tween 20 (Sigma-
Aldrich, USA) for 1 hour. Excess secondary antibody was also removed by washing of the membrane 
in 1×PBS/0.1%Tween 20 (Sigma-Aldrich, USA) (3 times for 10 minutes, with shaking). The bound 
antibodies were detected by chemiluminescence using chemiluminescence substrate solutions A and 
B (1:2) (LumiGloReserve, KPL Incorporated, USA) and the membrane was visualized using the UV 
transilluminator (Biospectrum
 
500 Imaging System, UVP, UK) and Visionworks LS Acquisition 
analysis software. The primary antibodies used were mouse monoclonal anti-DCUN1D1 (Santa Cruz 
Biotechnology Incorporated), rabbit polyclonal anti-GAPDH (Santa Cruz Biotechnology 
Incorporated) and mouse monoclonal anti-β tubulin (Santa Cruz Biotechnology Incorporated). The 
secondary antibodies used were goat anti-rabbit IgG HRP conjugates (Biorad, USA) and goat anti-
mouse IgG HRP conjugates (Biorad, USA).  
2.2 Determination of the relevance of DCUN1D1 for: proliferation, migration, 
apoptosis, and tumour formation in vivo 
2.2.1 Generation of DCUN1D1 knockdown cell lines 
In order to knockdown DCUN1D1 expression in DU145 and PC3 cells, short hairpin RNA (shRNA) 
was used to express small interfering RNA (siRNA) specific to DCUN1D1 in DU145 (DU145 
DCUN1D1-/-) and PC3 (PC3 DCUN1D1-/-) cells. Lentivirus vectors for human DCUN1D1 
(TRCN0000134715, Mission Lentiviral Transduction Particles, Sigma-Aldrich, USA) was used and 
green fluorescent protein (GFP) lentivirus vector was used as a control. DCUN1D1 lentivirus vector 
(2.3×10
7 
MOI) in DMEM (Gibco, Life Technologies, USA) was added to 70-80% confluent DU145 
and PC3 cells and allowed to transduce. Twenty four hours post transduction the cells were washed, 
collected using 0.05% Trypsin/EDTA (Gibco, Life Technologies, USA) and resuspended in complete 
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media. Cells expressing the DCUN1D1 or GFP lentiviral vector were selected for puromycin (Gibco, 
Life Technologies, USA) resistant growth in media supplemented with puromycin (Gibco, Life 
Technologies, USA). The concentration of puromycin used to ensure the selection of the resistant 
clones was determined to 1μg/ml. 
2.2.2 MTT Proliferation Assay 
Ninety six well tissue culture plates (SPL Life Sciences, Korea) were used to seed 2×10
3
cells/ well. 
Following drug treatment or reagent addition, 10μl yellow thiazoyl blue tetrazolium bromide (MTT) 
(5mg/ml) dissolved in sterile 1×PBS pH7.4 was added to the cells and incubated for 4 hours, in order 
quantify cell proliferation. The yellow MTT solution was converted into dark blue/purple formazan 
crystals by mitochondrial dehydrogenases of live actively metabolising cells and was solubilised 
following the 4 hour incubation by the addition of 100μl of solubilisation reagent (10% SLS, 0.01M 
HCl in dH2O) and incubation for 16 hours. Following this, the absorbance at 595nm was measured 
using a Multiskan
 
FC microplate photometer.  
2.2.3 Quantification of cell migration using transwell chambers 
Cell migration was tested using a modified transwell chamber migration assay (8μm pore size 
membrane, BD Biosciences). DU145 and DU145 DCUN1D1-/- (2,5x10
5
 cells) were seeded in serum-
free medium into the upper chamber and allowed to migrate toward 10% FBS as a chemoattractant in 
the lower chamber for 16 hours. Cells in the upper chamber were carefully removed using cotton 
swabs, and cells at the bottom of the membrane were fixed with ice-cold methanol and stained with 
DAPI. Ten different fields were randomly selected and the cells were counted in a fluorescence 
microscope (Karl Zeiss). 
2.2.4 Apoptosis Assay 
Twelve or six well tissue culture plates were used to seed 1×10
5
cells/ well. Following attachment and 
24 hour drug treatment of the cells, 1×10
5 
cells were harvested from each sample and transferred to 
1.5ml tubes. The cells were then collected following centrifugation at 3000×g for 2 minutes, 
following which they were incubated in 200μl lysis buffer for 30 minutes at 23°C. The lysate was 
then centrifuged at 200×g for 10 minutes in order to collect mono and oligonucleosomes enriched in 
the cytoplasm following apoptosis induction. These were present in the supernatant, from which 20μl 
was removed and added to the microplate. This was followed by addition of 80μl of immunoreagent 
[anti-histone-biotin antibody, anti-DNA-POD (anti-DNA-horse radish peroxidase) and incubation 
buffer)] to the microplate which was covered with adhesive cover foil and incubated with shaking at 
100rpm for 2 hours at 23°C. Streptavidin on the microplate binds anti-histone-biotin which binds the 
exposed DNA-bound histones in the sample. DNA within the histone-nucleosome is then bound by 
anti-DNA-POD. After the incubation period, the solution was removed by tapping on a water towel 
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and rinsed carefully, 3 times with 300μl incubation buffer. One hundred microlitres of the 2,2'-azino-
bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) solution was then added to initiate colour 
development and quantify apoptosis under the different experimental conditions. The reaction was 
then inhibited by the addition of 100μl ABTS stop solution. The absorbance at 405nm and the 
background absorbance at 492nm were measured, where high absorbance rates indicated high 
apoptosis induction. This procedure was performed as described in the Cell Death Elisa Plus kit 
(Roche, Germany).  
2.2.5 Subcutaneous implantation of MF1 nude mice 
Eight week old MF1 beige mice were bred in the University of Cape Town (UCT) animal facility 
under pathogen free environmental conditions. Immediately prior to implantation of DU145 cells, the 
cells were infected with lentivirus shRNA against DCUN1D1 and control GFP.  They were harvested 
using 0.05% Trypsin/EDTA (Gibco, Life Technologies, USA) and resuspended in DMEM (Gibco, 
Life Technologies, USA), containing 10% FBS (Biochrom AG, Berlin) and 1% penicillin 
(5000μg/ml)/streptomycin (500μg/ml) (Lonza, Walkersville MD, USA). The trypan blue stain 0.4% 
(Molecular probes, Life Technologies, USA) was used to measure cell viability in order to implant 
>90% viable cells into the animals.  Briefly, DU145 PCa cell lines and DU145 DCUN1D1 
knockdown cell lines were implanted through subcutaneous injection into MF1 beige mice on the first 
day (day 0). The cells (2x10
6
) were dissolved in 100µl of 1×PBS pH7.4 and injected using a 30 gauge 
needle over the flank of each animal and proper inoculation of the cell suspension was indicated by 
blebbing under the skin. All of the procedures were performed under aseptic conditions. Ten animals 
were used per group and tumour progression was monitored on a weekly basis. The animals were then 
sacrificed at the completion of the experiment (2 months later) where the tumours were excised, 
weighted and the animal was examined for possible distal metastasis. All of the procedures with the 
animals were reviewed and approved by the UCT Faculty of Health Sciences Animal Research Ethics 
committee. (See Appendix 8.5) 
2.3 Determination of DCUN1D1 signalling pathways in microarray analysis. 
In order to determine the role of DCUN1D1 on genome wide PCa gene expression we infected 
DU145 cells with shRNA DCUN1D1 and GFP 16 hours post seeding. The cells were then incubated 
for 24 hours following which the media was replaced and the cells were allowed to proliferate for 48 
hours. Total RNA was then extracted from the cells using Qiashredder (Qiagen, Valencia, CA, USA) 
and the RNeasy mini kit (Qiagen, Valencia, CA, USA) as described in section 2.1.3 and converted 
into cRNA as prescribed by the manufacturer (Affymetrix). The experiments were done in duplicates.  
The microarray analysis was performed at the Genomics, Proteomics, Bioinformatics and Systems 
Biology Centre at the Beth Israel Deaconess Medical Centre. The Affymetrix Human Transcriptome 
Array U133AAofAv2 GeneChips was used for gene transcript profiling of more than 30 000 probe 
31 
 
sets. Following generation of clean, intact RNA, 100ng total RNA was converted into complementary 
RNA (cRNA) according to the Affymetrix GeneChip WT Plus Reagent kit protocol. This involved 
conversion to double-stranded cDNA, in vitro transcription and labeling to synthesize amplified 
biotin-labelled antisense mRNA or cRNA. The cRNA, which is the reagent for microarray analysis, 
was then fragmented into 50-200 base pair fragments and hybrized onto the WT array (Affymetrix). 
The hybridization allowed for binding of the cRNA to specific probe pairs and gene transcript 
recognition. Excess cRNA was washed off, the array fluorescently stained and the stain amplified to 
produce different colour arrays. Confocal laser scanning was used to quantify the fluorescent levels, 
distribution patterns and subsequent transcript levels. Control samples were used at each step. 
Bioconductor affyQCReport software was used to determine the quality of the chip, Robust Multi-
array Average (RMA) algorithms were used for background correction, normalization and 
summarization of signal values. The scanned array image values were cross validated using model-
based expression analysis and statistical analysis by dChip (Zerbini et al., 2006). The samples were 
checked for reproducibility using correlation and signal-to-noise ratio (SNR) methods for replicate 
arrays. The Database for Annotation, Visualization and Integrated Discovery (DAVID) was used to 
identify Gene Ontology (GO) categories overrepresented in differentially expressed genes. The 
commercial systems biology package Ingenuity Pathways Analysis (IPA) was used to analyze the 
interactive networks identified. It calculates the p value for each network and compares the fit of our 
data to the profiles in the IPA database. The results are displayed as a –log p value score which 
indicates the likelihood of a gene being found in the network of a pathway by chance. Low p values 
indicate high confidence that data was not generated by random chance alone. The analysis will 
provide insight into statistically significant, highly affected (over-represented) GO biological 
processes/functions and canonical pathways among the predicted microarray target genes and this will 
help in determining the phenotypic changes observed. 
2.4 Connectivity map database analysis 
2.4.1 Identification of drugs for in vitro analysis  
The connectivity map database was used in order to identify DCUN1D1 specific inhibitors of PCa. 
The database allowed us to employ a genomics approach to drug discovery by using the gene 
expression signature obtained in the microarray analysis described above to find drugs. The list of up 
and downregulated genes obtained was uploaded onto the database according to the probe set number 
of the genes as described in the Affymetrix GeneChip array and based on fold change in gene 
expression (>2 fold change). The input gene query signature and the spectrum of profiles available in 
the database were then compared. The output produced consisted of compounds listed according to 
their enrichment scores and p values, which indicated the correlation between the compound and the 
input query signature. The enrichment scores range between +1 and -1 indicating a positive or 
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negative correlation with the query signature profile. A zero or ‘null’ score was also allocated which 
indicates no alteration following expression of the query signature. The compounds, in this case the 
drugs, with a positive correlation were selected for in vitro analysis.  The top 120 compounds with a 
positive correlation to our query signature were identified and 30 of these drugs were purchased for 
analysis. Some of these drugs were under patent restrictions or were not commercially available 
therefore the drugs finally tested in the study were the highest scoring drugs commercially available. 
2.4.2 Drugs 
The final concentrations, catalog number and names of the drugs used in the study were: anisomycin 
(6.25μM) (A9789), monensin (12.5μM) (M5273), lasalocid (7μM) (33339), podophyllotoxin 
(6.25μM) (P4405), thapsigargin (10nM) (T124), lycorine (12μM) (L5139), econazole (9μM)  
(E4632), biperiden (11μM) (B5311),  eticlopride (11μM) (E101), cyclobenzaprine (13μM) (C4542), 
guanabenz (14μM) (G110), sulfadimethoxine (12.5μM) (S7007), vinblastine (100nM) (V1377), 
clorsulon (12.5μM) (33973), trihexyphenidyl (12.5μM) (T1516), E. fumarate (12.5μM) (E100), 
colistin (3.125μM) (C4461), naringenin (12.5μM) (W530098), acemetacin (12.5μM) (A1674), 
chenodeoxycholic acid (12.5μM) (C9377), etiocholanolone (12.5μM) (E5126), folic acid (12.5μM) 
(F7876), guanabenz (12.5μM) (G110), terazosin (12.5μM) (T4680), dapson (12.5μM) (46158), 
isocarboxazid (12.5μM) (CDS020459), pyrithyldione (25μM) (R279072), nadolol (13μM) (N1892), 
vigabatrin (31μM) (V8261), gentamicin (12.5μM) (G1272) and josamycin (6.25μM) (59983). All of 
the drugs were obtained from Sigma-Aldrich, France.  The control used was 0.1% dimethyl sulfoxide 
(DMSO) (Sigma-Aldrich, France). 
Combination studies were performed with monensin (1μM and 2μM) and podophyllotoxin (15nM and 
30nM). 0.1% DMSO (Sigma-Aldrich, France) was used as a vehicle control. 
2.4.3 Calculating IC50s using GraphPad Prism version 5.01 
The MTT proliferation assay was performed to determine the dose dependent effect of the drugs on 
PCa cell proliferation. The concentrations of monensin and podophyllotoxin used in the combination 
study were based on the IC50s of each drug and the minimum concentration to inhibit proliferation 
monensin (1μM, 2μM) and podophyllotoxin (15nM, 30nM). Each experiment was performed in 
triplicate then GraphPad Prism version 5.01 for Windows (GraphPad Software, San Diego California, 
USA) was used to construct a sigmoidal dose response curve (variable slope)  and non-linear 
regression was used as a fit for the data.  
2.4.4 Isobologram 
In order to analyse the combined effect of monensisn and podophyllotoxin treatment on PCa, we 
performed an isobologram using Calcusyn software (Biosoft). The isobologram is a graphical 
representation of the interaction between two drugs and is formed by plotting the individual drug 
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doses required to achieve a single agent effect on their respective x and y axes, drawing a line to 
connect the two points (known as the line of additivity) and plotting the concentrations of the two 
drugs used in combination to achieve the same effect on the isobologram. Combination data points 
that fall on the line represent an additive interaction, whereas points above or below represent 
antagonism or synergy, respectively. 
2.4.5 Statistical analysis: Paired t-test 
The proposal investigated in this study was whether DCUN1D1 plays a role in PCa development and 
progression. Therefore the methodology used, as described in this section, was aimed at establishing 
whether there was any significant difference in DCUN1D1 expression in human PCa cell lines or 
human tissue samples relative to normal samples and whether this difference contributed to the 
growth of prostate tumours. It also aimed to determine if the drugs identified as DCUN1D1 inhibitors 
using the cmap database significantly inhibited PCa growth in a DCUN1D1-dependent manner. 
Therefore, our investigations involved comparisons of two data sets including a group representing a 
reference standard and a group representing the experimental conditions. The averages (means) of the 
2 data sets were compared; therefore we used the paired t-test in order to determine if the differences 
we observed in the experiments were statistically significant. We chose this model because we were 
comparing two paired/matched data sets by calculating their means and calculating the standard 
deviation as a measure of variability within each data set. In addition, because we were not only 
interested in whether there was an association between the two data sets but also the nature of the 
association, higher or lower, we chose the two tailed distribution.  
Therefore with a null hypothesis stating that there is no difference between the matched pairs, based 
on two-tailed normal distribution and a 95% confidence interval, we used the paired two sample t-test 












Chapter 3: Results 
3.1 Differential expression of DCUN1D1 in prostate cancer. 
3.1.1 DCUN1D1 is upregulated in human prostate cancer cell lines. 
DCUN1D1 is deregulated in several different types of cancers including head and neck and lung 
carcinomas (Sarkaria et al., 2006). However, its expression level and its role in PCa are unknown. In 
order to evaluate DCUN1D1 expression in PCa, we screened a variety of PCa cell lines. Using 
quantitative real time PCR and western blot analysis, four androgen dependent (CW22, CW19, 
LNCaP and VCaP), four androgen independent PCa cell lines (DU145, DUCaP, PC3 and CL1) and a 
normal epithelial prostate cell line, PREC were evaluated for DCUN1D1 mRNA and protein 
expression. This includes CL1, a clonal cell line, which was generated upon conversion of the 
androgen-sensitive LNCaP cells to an androgen-insensitive state by the removal of androgen in the 
media. We observed upregulation of DCUN1D1 especially in the androgen independent DU145, 
DUCaP, PC3 and CL1 PCa cell lines relative to normal cell lines (Figure 7A and B). Quantitative real 
time PCR analysis showed DCUN1D1 mRNA expression fold induction of 3-4 folds in the androgen 
independent PCa cell lines with lesser levels in the androgen dependent cell lines. In addition, within 
the androgen dependent cell lines the cell line representative of more aggressive PCa, VCap, showed 
higher levels of DCUN1D1 expression. LNCap also showed DCUN1D1 upregulation. Western blot 
analysis showed similar alterations in the protein levels of DCUN1D1 with DU145, PC3, DUCaP, 
CL1, VCaP and LNCap showing significant upregulation of DCUN1D1 protein. These findings 
indicate that DCUN1D1 is upregulated in PCa cells and may play a role in PCa. 
3.1.2 DCUN1D1 is upregulated in human prostate cancer tissue. 
In order to corroborate the observations made in tissue culture cell lines, we evaluated DCUN1D1 
expression levels in human tissue samples. A commercially available panel of 96 human tissue 
samples (OriGene TissueScan Prostate Cancer Tissue Array I and II) was used which contains cDNA 
from adenocarcinoma of the prostate, BPH, normal tissue and tissue from other disease controls 
(bladder carcinoma tissue). Quantitative real time PCR analysis of DCUN1D1 expression found that 
42% of the adenocarcinoma tissue samples stages I, II and III showed upregulation of DCUN1D1 
relative to normal tissue (Table 1). In addition, immunohistochemistry analysis of DCUN1D1 
expression using anti-DCUN1D1 antibody in a separate cohort of 16 human tissue samples was 
performed with the assistance of Dr Yihong Wang at Brown University, USA. Seven out of the 16 
(43.7%) samples showed positive staining for DCUN1D1 (Figure 8). These data provide further 





Table 1. Real time PCR analysis of DCUN1D1 gene expression in human prostate cancer tissue. 
Tissue type 
Number of upregulated 
samples/number of samples (%) 
Fold induction compared to 
normal prostate tissue 
Adenocarcinoma of prostate 
(stages I, II and III) 
29/69 (42%) 2 to 2000 
BPH 0/10 (0 %) 0 
Carcinoma of bladder, transition 
tissue 





Figure 7. Regulation status of DCUN1D1 in prostate cancer cell lines. A) Quantitative real 
time-PCR analysis of DCUN1D1 in prostate cancer cell lines. Total RNA was collected from 
PREC (normal), DU145, DUCaP, PC3, CL1 (androgen independent) and CW22, CW19, LNCaP, 
VCaP (androgen dependent) cells. Normalization of each sample was carried out by measuring the 
amount of β-tubulin complementary DNA. B)  Western blot analysis of DCUN1D1 expression in 
the same prostate cancer cell lines. DCUN1D1 expression was probed with anti-DCUN1D1 






3.2 Blockage of DCUN1D1 inhibits proliferation and migration of prostate cancer cells. 
DCUN1D1 overexpression has previously been implicated in proliferation and migration of cancer  
cells (O-charoenrat et al., 2008; Broderick et al., 2010), therefore we explored these effects in PCa. In 
order to establish the relevance of DCUN1D1 in PCa proliferation and migration, we generated 
DU145 and PC3 cells with the DCUN1D1 gene knocked down (DU145 DCUN1D1 -/- or PC3 
DCUN1D1-/-) using a lentivirus vector (Mission Lentiviral Transduction Particle, Sigma-Aldrich) 
specific to DCUN1D1 and green fluorescent protein (GFP) (DU145 or PC3), as the control. Infection 
of DU145 and PC3 with DCUN1D1 shRNA lentivirus (LV-shRNA) resulted in 95% reduction of 
DCUN1D1 expression confirmed at the mRNA and protein levels using quantitative real time PCR 
and western blot analysis respectively, (Figure 9). Inhibition of DCUN1D1 strongly reduced 
proliferation of DU145 and PC3 PCa cells (Figure 10). Additionally, DCUN1D1 knockdown strongly 
reduced the migratory capabilities of DU145 and PC3 cells after 24h hour incubation; when compared 
to DU145 and PC3 cells infected with LV-shRNA GFP. These results demonstrate that DCUN1D1 is 







Figure 8. DCUN1D1 is upregulated in prostate cancer tissue. Immunohistochemical staining 
of prostate cancer biopsies. A) Staining of DCUN1D1 in normal and prostate cancer tissue 







Figure 9. Blockage of DCUN1D1 in DU145 and PC3 prostate cancer cells lines. Prostate 
cancer cells were infected with lentivirus encoding shRNA against GFP and DCUN1D1. A) Real 
time-PCR analysis of DCUN1D1 in prostate cancer cell lines. Total RNA was collected from 
DU145 and PC3 cell lines and normalized by measuring the amount of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) complementary DNA. B) Western blot analysis of 
DCUN1D1 expression in DU145 and PC3 cell lines. DCUN1D1 expression was probed with 
anti-DCUN1D1 antibody and normalized by measuring the amount of glyceraldehyde-3-





3.3 Inhibition of DCUN1D1 leads to the induction of apoptosis in prostate cancer cells. 
We used the same siRNA approach to determine whether blockage of DCUN1D1 would induce 
apoptosis in DU145 PCa cells. The Cell Death Elisa Plus kit (Roche, Germany) was used to quantify 
the induction of apoptosis in DU145 and DU145 DCUN1D1-/- cell lysates. Blockage of DCUN1D1 
resulted in the induction of apoptosis when compared to cells infected with control siRNA (Figure 
11).   
Figure 10. Blockage of DCUN1D1 expression inhibits proliferation and migration in prostate 
cancer cell lines. DU145 and PC3 cell lines were infected with lentivirus encoding shRNA against 
GFP and DCUN1D1. A) Proliferation of DU145 and PC3 48h post-infection. B) Migration of 
DU145 and PC3 cell lines was measured 48 hours post-infection in transwell plates. Data means 





3.4 DCUN1D1 is essential for in vivo prostate cancer tumour growth. 
Having established the importance of DCUN1D1 for in vitro PCa growth, we determined whether 
inhibition of DCUN1D1 affects tumour formation in MF1 nude mice. Using xenograft mice models, 
DU145 cells infected with DCUN1D1 shRNA lentivirus (DU145 DCUN1D1-/-) and shGFP (DU145) 
were subcutaneously implanted into eight week old male MF1 mice and 2 months later, the mice 
were sacrificed, examined for tumour formation and the tumour weighted. As observed in figure 12, 
in contrast to the control cells, blockage of DCUN1D1 significantly reduced tumour growth with a 
58% reduction in tumour weight observed. This has not been observed previously and it clearly 





























Figure 11. Blockage of DCUN1D1 expression induces apoptosis in prostate cancer cell lines. 
DU145 cell lines were infected with LV-shRNA DCUN1D1 (DU145 DCUN1D1-/-) and LV-
shRNA GFP (DU145) as the control. The Cell Death Elisa Plus kit was used to quantify apoptosis 





3.5 Microarray analysis of DCUN1D1 knockdown in prostate cancer cells. 
DCUN1D1 has been shown to perform E3 ligase activity in cullin neddylation. However, apart from 
identifying direct binding of DCUN1D1 and cullin 1-5, no other proteins have been identified as 
DCUN1D1 substrates and little is understood about its activity (Kim et al., 2008). The main objective 
in performing the microarray analysis was to understand which biological pathways are being 
regulated by DCUN1D1 in PCa and which genes are affected by DCUN1D1 expression, in order to 
obtain a DCUN1D1 -/- gene signature for use in the connectivity map database for the identification 
of DCUN1D1-dependent inhibitors of PCa. RNA from DU145 cells infected with LV-shRNA 
DCUN1D1 specific sequences were hybridized to Affymetrix HT U133AAofAv2 GeneChips which 
contain more than 30 000 probe sets. DCUN1D1 knockdown resulted in the downregulation of 244 
genes and the upregulation of 78 genes (≥2 fold change). DCUN1D1 and related analogues have been 
associated with development and developmental pathways (Kurz et al., 2005; Huang et al., 2011) and 
similarly, functions associated with development were deregulated upon DCUN1D1 knockdown in 
DU145 PCa cells. Figure 13 and 14 show the top 10 functions and pathways predicted to be 
deregulated upon DCUN1D1 knockdown. Gene expression, cellular growth and proliferation, 6 
development, cell death and cancer related functions were deregulated. Concurrently, axonal 
guidance, TR/RXR activation, semaphorin, Wnt/β-catenin, sonic hedgehog signalling pathways were 
identified which suggests the pathways mediating the developmental functions. PKA, cyclins and cell 
cycle related pathways were also predicted to be deregulated which suggests the possible mechanisms 























Figure 12. Inhibition of DCUN1D1 reduces tumour formation in MF1 nude mice. DU145 
cells (2×10
6
) infected with LV-shRNA DCUN1D1 (DU145 DCUN1D1-/-) or LV-shRNA GFP 
(DU145) were implanted subcutaneously into MF1 nude mice. The tumour weight was measured 2 





similar to the maturity onset diabetes of young (MODY) pathway were also among the top 10 
pathways deregulated. These alterations appear to result in the phenotypic deregulation of the 
molecular mechanisms of cancer. In addition, the predicted functions and pathways are also reflected 
in the top 10 up and downregulated genes following DCUN1D1 knockdown (Table 2) (See Appendix 
8.1 and 8.2 for top 50 up and downregulated genes). Interesting, among these genes are UBE2C and 
UBE2J2 which are up and downregulated respectively following DCUN1D1 knockdown. These 
genes are both E2 ubiquitin conjugating enzymes which also suggests the deregulation of the 
ubiquitination pathway (Townsley et al., 1997; Oh et al., 2006). Therefore, DCUN1D1 knockdown 




Figure 14. Bioinformatics analysis of the top 10 pathways deregulated following DCUN1D1 
knockdown in DU145 prostate cancer cells. The list of genes up- and down-regulated in DU145 
cells expressing the DCUN1D1 shRNA were imported into the Ingenuity Pathway Analysis tool 
and canonical pathways were determined. Output represents top 10 deregulated pathways 
expressed as –log (p-value). 
  
Figure 13. Bioinformatics analysis of the top 10 functions deregulated following DCUN1D1 
knockdown in DU145 prostate cancer cells. The list of genes up and down-regulated in DU145 
cells expressing the DCUN1D1 shRNA were imported into the Ingenuity Pathway Analysis tool 
and functions affected were determined. Output represents top 10 deregulated functions expressed 
as –log (p-value). 
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Table 2:  List of top 10 up and downregulated genes after inhibition of DCUN1D1 
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3.6 Screening of drugs for DCUN1D1 specific anti-prostate cancer activity. 
In order to identify compounds that can potentially be used to inhibit PCa growth in a DCUN1D1-
dependent manner, we used the connectivity map (cmap) database. As described previously, we 
performed microarray analysis of DU145 and DU145 DCUN1D1-/- cells and obtained a list of genes 
up and downregulated upon DCUN1D1 knockdown (>2 fold change). This allowed us to select a gene 
signature that is more specific to the effect of DCUN1D1 inhibition. Using the probe set number of 
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these genes as described by Affymetrix Human Transcriptome Array U133AAofAv2 GeneChips we 
uploaded the gene expression profile into the cmap database and obtained a list of compounds 
positively or negatively correlated with our query signature. Of the 1309 bioactive small molecules 
present in the database the pattern matching algorithms identified the compounds based on 
statistically significant changes represented by p-values and enrichment scores. The enrichment scores 
ranged between +1 and -1 indicating a positive or negative correlation with the query signature 
profile. As we are searching for compounds that lead to the same effect as inhibition of DCUN1D1, 
we focused on compounds with positive enrichment scores (i.e. positive correlation with the profile 
obtained upon DCUN1D1 knockdown under our experimental conditions). In our first analysis, we 
selected the top 120 small molecule compounds with a highly significant positive score to our query 
signature. Nadolol had the highest positive score of 0.911 while vinblastine the compound ranked 30
th
 
on our list had a positive score of 0.727. Some of the compounds identified are under patent 
restriction or were not commercially available therefore; we were able to obtain 30 drugs (listed in 
Table 3) and performed in vitro analysis on them. The compounds used in this study include 
microtubule inhibitors, protein and DNA synthesis inhibitors, ion channel inhibitors, neurotransmitter 
agonists/antagonists, anti-inflammatory drugs, antibiotics, an amino acid/ nucleotide synthesis 
promoter, a liver fluke specific drug and a testosterone metabolite (Table 4). We provide a schematic 
diagram showing the approach we applied in screening the drugs. Briefly, we first determined 
whether a compound inhibits PCa cell proliferation and/or induces apoptosis of PCa cells, then we 
evaluated the effect of the drugs in cells lacking DCUN1D1 expression in order to determine whether 















Table 3:  30 drugs identified through the connectivity map database using p-values and score 
Drug Score P-value  Drug Score P-value 
       
Vinblastine 0.73        0.04  Clorsulon 0.82  0.002 
Lycorine 0.67         0.01  Biperiden 0.74 0.003 
Anisomycin 0.77         0.005  Gentamicin 0.78  0.004 
Lasalocid 0.77   0.005  Chenodeoxycholic 
acid 
0.75  0.007 
Thapsigargin 0.79      0.02  Isocarboxazid 0.66  0.012 
Podophyllotoxin 0.80       0.003  Colistin sulfate 0.72  0.01 
Cyclobenzaprine 0.73        0.01  Sulfadimethoxine 0.67  0.01 
Monensin 0.79     0.0002  Dapson 0.68 0.008 
Folic acid                0.67       0.028  Etiocholanolone 0.71  0.002 
Econazole 0.68        0.02  E. fumarate 0.79 0.02 
Guanabenz 0.73    0.003  Trihexypheidyl 0.80  0.02 
Acetemacin 0.67      0.027  Josamycin 0.74 0.003 
Eticlopride 0.75       0.008  Vigabatrin 0.79 0.018 
Terazosin 0.68         0.02  Nadolol 0.91  0.00006 






















Drug Description References 
Vinblastine   Alkaloid extracted from Catharanthus roseus; inhibits microtubule assembly causing metaphase arrest 
 Anticancer activity against lympoid, cervical cancer, neuroblastoma and PCa 
 (Jordan et al., 1991; Jordan et al., 1992; Toso et al., 1993; 
Vacca et al., 1999; Klement et al., 2000) 
Lycorine   Alkaloid extracted from Amaryllidaceae plants; inhibit protein synthesis, impairs actin cytoskeleton organization; weak inhibitor of 
acetylcholinesterase activity 
 Antiviral, antimalarial, antiinflammatory,  potent anticancer agent against glioblastoma, NSCLC, oesophageal cancer and melanoma  
(Vrijsen et al., 1986; Tanker & Gu, 1998; Sener et al., 
2003; Lamoral-Theys et al., 2009; McNulty et al., 2010)  
Anisomycin   Antibiotic isolated from Streptomyces griseolus; potent, reversible inhibitor of DNA and protein synthesis; pro and antiapoptotic 
mechanisms 
 Antiprotozoal; sensitizes PCa cells to apoptosis, anticancer activity against HL60 
 (Grollman, 1967; Hazzalin et al., 1998; Törocsik & 
Szeberényi, 2000; Curtin & Cotter, 2002; Stadheim & 
Kucera, 2002)  
Lasalocid   Antibiotic isolated from Streptomyces lasaliensis; carboxylic ionophore; reversible effect on Golgi apparatus 
 Feed additive to prevent coccidiosis in chickens, horses and cows; toxic to horses and cattle 
(Haskell et al., 1965; Somlyo et al., 1975; Jonakait et al., 
1979; Hanson & Eisenbeis, 1981; Blanchard et al., 1993)   
Thapsigargin   Sesquiterpene lactone derived from the roots of Thapsia garganica; selective inhibitor of sarco-endoplasmic reticulum Ca2+-ATPases 
(SERCAs), targets calmodulin 
 Anticancer activity against PCa,  NSCLC, glioblastoma cancer but toxicity reported and resistance evident; induces apoptosis even in 
senescent cells 
(Tombal et al., 2000; Kovacs et al., 2005; O’Neill et al., 
2006; Linxweiler et al., 2013)  
Podophyllotoxin  Naturally occurring lignan found in Podophyllum plants; inhibits tubulin polymerization to induce cell cycle arrest and apoptosis in 
cancer cells 
 Topical gel to treat genital warts, antiviral, anticancer activity 
 (Jordan et al., 1992; Strand et al., 1995; Imbert, 1998)  
Cyclobenzaprine   Anticholinergic activity 
 Skeletal muscle relaxant used in the treatment of musculoskeletal pain; structurally similar to tricyclic antidepressants  
 (Brioschi et al., 2013) 
Monensin  Antibiotic isolated from Streptomyces cinnamonensis; carboxylic ionophore that disrupts Golgi apparatus structure and inhibits vesicular 
transport in eukaryotes; inhibits androgen signalling  
 Antiprotozoan, antibacterial and antifungal; specific anticancer activity in PCa, lymphoma, lung, colon and renal cancer through cell 
cycle arrest, oxidative stress and induction of autophagy or apoptosis 
 (Russell, 1987; Mollenhauer & Morré, 1990; Park et al., 
2002; Park et al., 2003; Park et al., 2003; Ketola et al., 
2010; Choi et al., 2013)  
Folic acid   Found in fruit and vegetables; required for synthesis of thymidylate, purine nucleotides, serine and methionine 
 Essential for cell growth and development; contradictory evidence on tumourigenesis 
 (Huennekens & Duffy, 1987; Butterworth et al., 1992; 
Bandera et al., 1997; Feigelson et al., 2003)  
Econazole   Imidazole; interacts with mammalian ion channels particularly Ca2+ ion channels; affects calcium signalling 
 Antifungal, antibacterial, antitubercular activity, anticancer activity against  PCa, leukemia, breast; evidence of resistant 
 (Gamberucci et al., 1998; Jan et al., 1999; Hill et al., 
2004; Huang et al., 2005; Yu et al., 2008; Slagsvold et al., 
2009; Kim et al., 2012)  
Guanabenz   α2-adrenergic agonist; inhibits hepatic cholesterol production, triglyceride synthesis and stimulates fatty acid oxidation 
 Treatment of hypertension; antiprion activity 
(Meacham et al., 1980; Misu & Fujie, 1982; Capuzzi, 
1984; Tribouillard-Tanvier et al., 2008)   
Acemetacin   Cyclo-oxygenase inhibitor; prodrug for indomethacin; inhibition of gastric prostaglandin PG synthesis and human leukocyte PG synthesis  
 Analgesic, non-steroidal anti-inflammatory drug (NSAID); used against rheumatic disease and musculoskeletal disorders 
(Chou, 2002; Chávez-Piña et al., 2007; Gil-Flores et al., 
2010)  
Eticlopride   Selective dopamine (DA) D2-like receptor inhibitor 
 Antipsychotic agent but primarily used to study receptor activity in schisophrenia and other brain disorders 
 (Seeman, 1988; Giuliani & Although, 1995; Giuliani & 
Ferrari, 1997) 




Terazosin  α1-adrenergic receptor antagonist 
 Treatment of BPH and hypertension;induces apoptosis in PCa and bladder cancer cells 
 (Lepor et al., 1992; Itskovitz, 1994; Kyprianou, 2003; 
Tahmatzopoulos et al., 2005)  
Naringenin   Flavonoid derived from citrus, grapefruits and juices 
 Antiinflammatory activity; antitumour activity against PCa, breast, stomach and liver cancer 
(Kanno et al., 2005; Choi et al., 2007; Knowles et al., 
2009; Coelho et al., 2013) 
Pyrithyldione   Psychoactive drug; used as hypnotic or sedative. No longer used  (Becker & Fabing, 1949) 
Clorsulon   Inhibitor of phosphoglycerate kinase and phosphoglyceromutase of Fasciola liver flukes 
 Antiparasitic  
 (Schulman, 1982; Schulman & Ostlind, 1982; Elitok & 
Elitok, 2006; Escribano et al., 2012)  
Biperiden   Muscarinic receptor antagonist 
 Antiparkinsonian; treatment of neuroleptic-induced Tardive dyskinesia, schizophrenia or otherchronic mental illnesses 
(Eltze, 1988; Jackisch et al., 1994; Silver & Geraisy, 1995)  
Gentamicin   Antibiotic synthesized by Micromonospora 
 Inhibits protein synthesis through binding to bacterial ribosome 30S subunit 
 (Barber & Waterworth, 1966; Weinstein et al., 1967; 
Buss, 1985)  
Chenodeoxycholic   
acid 
 Synthesized mainly from dietary cholesterol;  
 Treatment of bilary disruptions, gallstones; inhibits inflammation; carcinogenesis 
(Bell et al., 1974; Ayaki e et al., 1981; Martin et al., 1981; 
He et al., 2011; Odunsi-Shiyanbade et al., 2011)   
Isocarboxazid  Monoamine oxidase inhibitor of  the brain, heart, and liver; catecholamine transferase inhibitors  
 Antidepressant; anxiolytic (antianxiety agent) 
 (Gardner et al., 1960; Joshi, 1961; Barber et al., 1962; 
Giller et al., 1982)  
Colistin sulfate  Antibiotic isolated from Bacillus polymyxa  
 Active against multidrug resistant organisms; used for cystic fibrosis treatment 
 (Komura, 1979; Reed et al., 2001; Pitt et al., 2003; 
Sabuda  et al., 2008) 
Sulfadimethoxine   Antibiotic; inhibits bacterial folic acid synthesis 
 Antibacterial; used in veterinary medicine in the treatment of different species of animals with coccidial (microscopic parasite) infections; 
antithyroid activity 
 (Schnitzer et al., 1958; Stowe, 1963; Bridges et al., 1968; 
Nishikawa, 1983; Mitrovic & Bauernfeind, 2014)  
Dapson  Antibiotic, antiinflammatory 
 Used primarily for treatment of Dermatitis herpetiformis (leprosy); used in combinations as antimalarial 
(Debol & Herron, 1997; Winstanley et al., 1997; Deps et 
al., 2012)  
Etiocholanolone  Testosterone metabolite; epimer of androsterone a GABAA receptor modulator and precursor of testosterone in PCa tumours 
 Anticonvulsant properties, no information on its activity just that it is a metabolite and it’s steroidgenesis 
 (Kaminski et al., 2005) 
E. fumarate   Anticholinesterase; metabolite of  physostigmine;  
 Anticancer activity against mouse neuroblastoma and rat gliomas 
 (Fürst et al., 1982; Somani et al., 1990) 
Trihexyphenidyl   Muscarinic receptor antagonist 
 Used in the treatment of neurological movement disorders; antiparkinsonian disease 
 (Burke & Fahn, 1986; Giachetti et al., 1986; Takahashi et 
al., 1999)  
Josamycin  Antibiotic produced by Streptomyces narbonensis. 
 Used as antibacterial agent 
 (Strausbaugh et al., 1976; Privitera & Bonino, 1984; See 
et al., 2010) 
Vigabatrin  Irreversibly inhibits gamma aminobutyric acid (GABA) transaminase 
 Antiepileptic drug; used in the treatment of infantile spasms  
 (Lippert et al., 1977; Tartara et al., 1986; Elterman et al., 
2001)  
Nadolol   Non selective β1-adrenergic receptor inhibitor;   
 Used in the treatment of hypertension and angina (chest pain) and tremor 
 (Volicer et al., 1979; Wheeldon et al., 1994; Hanania et 
al., 2009)  
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3.6.1 Analysis of high scoring drug activity on prostate cancer cell proliferation. 
As an initial screening mechanism for drug activity, we performed analysis of proliferation using the 
MTT assay. This method allowed us to perform high throughput analysis of the inhibitory effect of 
the drugs at different concentrations and time points. All 30 drugs were used at the concentrations 
described in the cmap database for a period of 24 and 48 hours and among the selected drugs we 
identified 12 drugs (anisomycin, monensin, lasalocid, podophyllotoxin, thapsigargin, lycorine, 
vinblastine, econazole, eticlopride, cyclobenzaprine, guanabenz and biperiden) with significant 
growth inhibitory properties in PCa cells (Figure 16). In order to determine whether the inhibition of 
proliferation of PCa cells occurs in a DCUN1D1-dependent manner we evaluated the effect of the 
drugs on DU145 DCUN1D1 knockdown cell lines (DU145 DCUN1D1 -/-). We also evaluated 
whether these drugs were toxic to normal prostate cells. As observed in figure 17, anisomycin, 
thapsigargin, podophyllotoxin, lasalocid, monensin, econazole, biperiden, eticlopride and 
cyclobenzaprine inhibit proliferation of DU145 PCa cell proliferation but have no effect in DU145 
DCUN1D1 -/- cells. In addition, no inhibition of normal PNT1A cell proliferation was observed 
following treatment with these drugs (data not shown), indicating that these drugs may be inhibiting 
DU145 proliferation via DCUN1D1. Although vinblastine, lycorine and guanabenz show significant 
reduction of proliferation in DU145 cells, they were still effective against DU145 DCUN1D1-/- cells 
and vinblastine was toxic to PNT1A cells. Therefore, anisomycin, thapsigargin, podophyllotoxin, 
lasalocid, monensin, econazole, biperiden, eticlopride and cyclobenzaprine are the drugs which 



























Figure 16. Proliferation assay in DU145 prostate cancer cell lines using drugs at cmap 
concentrations. Proliferation assay 24 hours post drug treatment. Treatment with anisomycin 
(6.25μM), monensin (12.5μM), lasalocid (7μM), podophyllotoxin (6.25μM), thapsigargin (10nM), 
lycorine (12μM), econazole (12.5μM), biperiden (12.5μM), eticlopride (12.5μM), cyclobenzaprine 
(12.5μM), guanabenz (12.5μM), vinblastine (100nM), 0.1% DMSO as a vehicle control. Data shown 





3.6.2 Analysis of the induction of apoptosis in response to drug treatment. 
We also evaluated the effect of the high scoring drugs from our connectivity map analysis on the 
induction of apoptosis. A review of the literature revealed that some of the drugs (anisomycin, 
thapsigargin, monensin) from our analysis have growth inhibitory  effects on PCa cells (Tombal et al., 
2000; Stadheim & Kucera, 2002; Ketola et al., 2010). As observed in figure 18, treatment with 
anisomycin, monensin, podophyllotoxin, lycorine, vinblastine, biperiden, eticlopride, 
cyclobenzaprine, clearly induces apoptosis in PCa cells as measured using the Cell Death Elisa Kit 
(Roche). However, some of the drugs that demonstrated inhibition of proliferation such as lasalocid 
and thapsigargin did not induce apoptosis at the same concentrations (Figure 18) which could mean 
































Figure 17. Proliferation assay in DU145 prostate cancer and DU145 DCUN1D1 knockdown. 
DU145 cell lines were infected with LV-shRNA GFP (DU145) and LV-shRNA DCUN1D1 
(DU145 DCUN1D1 -/-) and were evaluated for their drug activity. Treatment with anisomycin 
(6.25μM), monensin (12.5μM), lasalocid (7μM), podophyllotoxin (6.25μM), thapsigargin 
(10nM), lycorine (12μM), econazole (12.5μM), biperiden (12.5μM), eticlopride (12.5μM), 
cyclobenzaprine (12.5μM), guanabenz (12.5μM), vinblastine (100nM) and 0.1% DMSO 
as a vehicle control. The MTT Proliferation assay was performed 24 hours post treatment. Data 
shown are mean±s.d. of triplicate independent experiments.  OD, absorbance. 
  







3.6.3 Analysis of high scoring drug activity on DCUN1D1 mRNA and protein expression. 
Since the objective of our study is to identify compounds that inhibit PCa growth through direct 
interference with DCUN1D1, we evaluated the effect of the 12 drugs from our connectivity map 
analysis on DCUN1D1 expression. Using RT-PCR we determined that monensin, lasalocid, 
podophyllotoxin, thapsigargin and vinblastine significantly reduced DCUN1D1 mRNA expression 24 
hours post treatment, while anisomycin and lycorine significantly increased DCUN1D1 expression 
(Figure 19 A) compared to the control treatment. The rest of the drugs did not alter DCUN1D1 
mRNA expression. Four of the drugs (monensin, lasalocid, podophyllotoxin and thapsigargin) that 
inhibited DU145 cell proliferation in a DCUN1D1 dependent manner also reduced DCUN1D1 
mRNA expression. Messenger RNA expression does not always correlate with protein expression, 
therefore we utilized the western blot technique to analyse the effects of the drugs on DCUN1D1 
protein expression. The same pattern of expression was not observed at the protein level. We observed 
reduced DCUN1D1 protein expression following treatment with anisomycin, monensin, 
podophyllotoxin, lycorine, guanabenz and vinblastine (Figure 19 B) and the opposite was true for 
thapsigargin, lasalocid, econazole, eticlopride, cyclobenzaprine and biperiden. Three of the drugs 
(anisomycin, monensin, podophyllotoxin) that mediated DCUN1D1-specific inhibition of PCa 
proliferation reduced DCUN1D1 protein expression. Although lycorine, guanabenz and vinblastine 





















Figure 18. Induction of apoptosis after treatment with high scoring drugs. Treatment with 
anisomycin (6.25μM), thapsigargin (10nM), podophyllotoxin (6.25μM), lasalocid (7μM), 
monensin (12.5μM), vinblastine (100nM), lycorine (12μM), econazole (9μM), biperiden (11μM), 
eticlopride (11μM), cyclobenzaprine (13μM), guanabenz (14μM) and 0.1% DMSO as a vehicle 
control. The Cell Death Elisa Plus kit was used to quantify apoptosis 24 hours post-seeding of the 
cells. * represents p<0.05  
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pass the screening process of our study as they did not mediate DCUN1D1-specific inhibition of 
DU145 proliferation (Figure 17) and vinblastine showed toxicity towards normal prostate cell. The 
objective of this study is to identify compounds that inhibit PCa growth through direct interference 
with DCUN1D1 and we determined this to be the criteria for further analysis: DCUN1D1-specific 
inhibition of proliferation, minimal toxicity in normal prostate cells; induction of apoptosis and 
reduction of DCUN1D1 mRNA and protein expression. In this regard, the only drugs that consistently 
fit our criteria were monensin and podophyllotoxin. 
 
 
Figure 19. DCUN1D1 expression in DU145 cells 24 hours post treatment with high scoring 
drugs. A) Real time-PCR analysis of DCUN1D1 in DU145 prostate cancer cell lines following 24 
hour treatment with anisomycin (6.25μM), monensin (12.5μM), lasalocid (7μM), podophyllotoxin 
(6.25μM), thapsigargin (10nM), lycorine (12μM), vinblastine (100nM), econazole (9μM), 
biperiden (11μM), eticlopride (11μM), cyclobenzaprine (13μM), guanabenz (14μM) with 0.1% 
DMSO as a vehicle control. Total RNA was collected from DU145 cell lines and normalized by 
measuring the amount of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) complementary 
DNA. Data shown are mean±s.d. of triplicate independent experiments. * represents p<0.05. B) 
Western blot analysis of DCUN1D1 expression in the DU145 PCa cells with the same drug set was 
performed. DCUN1D1 was probed using anti-DCUN1D1 antibody and normalized by measuring 
the amount of glyceraldehyde-3-phosphate dehydrogenase (GAPDH).  
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3.6.4 Combinatorial therapy studies 
As mentioned previously, using the connectivity map database we employed a genomics approach to 
drug discovery. After identifying the gene signature of DCUN1D1 knockdown in DU145 PCa cells, 
the drugs with a positive correlation to the signature were identified. Following initial screening using 
the MTT proliferation assay, 12 drugs were identified for further analysis and of these drugs, 9 
(anisomycin, thapsigargin, podophyllotoxin, lasalocid, monensin, econazole, biperiden, eticlopride 
and cyclobenzaprine) were determined to mediate DCUN1D1-specific inhibition of proliferation. Of 
these drugs, monensin, podophyllotoxin and anisomycin induced apoptosis in DU145 cells but most 
importantly monensin and podophyllotoxin treatment led to significant reduction in both DCUN1D1 
mRNA and protein (Table 5). Therefore, we selected monensin and podophyllotoxin for use in 
combination studies.  









DCUN1D1 protein  
Induction of 
Apoptosis 
Monensin  + + + + 
Biperiden  +     + 
Podophyllotoxin  + + + + 
Guanabenz          
Lasalocid  + +     
Anisomycin  +   + + 
Eticlopride   +     + 
Cyclobenzaprine  +     + 
Lycorine       + + 
 Thapsigargin  + +     
Econazole +       
Vinblastine    + + + 
 
In order to establish the IC50 of each drug, we performed a dose-dependent proliferation assay and 
used the GraphPad Prism version 5.01 software to perform the analysis (Figure 20 and 21).  The IC50s 
were determined to be 2μM for monensin and 30nM for podophyllotoxin. These drugs were then used 
in combination where DU145 PCa cells were treated with monensin 1μM and 2μM and 
podophyllotoxin 15nM amd 30nM, with 1μM and 15nM representing the lowest concentrations at 
which inhibitory activity is still observed. Combination of 1μM monensin and 15nM podophyllotoxin 
demonstrated significant reduction in DU145 proliferation when compared to the monotherapy 
(Figure 22) (p<0.001).  
The in vitro analysis performed on these two drugs indicates that both drugs are inhibiting PCa 
growth in a DCUN1D1-dependent manner and combinatorial analysis using the MTT proliferation 
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assay suggests that when used together, the drugs induce a statistically significant inhibitory effect on 
PCa proliferation. It is important to determine if the activity of the drugs is leading to a greater 
inhibitory effect due to combined general inhibitory effects (synergism) or if they are targeting the 
same pathway and are therefore having an additive effect.  Although we have shown that both drugs 
target DCUN1D1, it could be that DCUN1D1 is affecting a different set of target genes under the 
mechanism of action of each drug. We used isobologram analysis on Calcusyn3 software (Biosoft) to 
determine the theoretical combinatorial effect of monensin and podophyllotoxin on DU145 
proliferation. The dose equivalence of each drug was analysed and a linear additive isobole was 
generated to determine the effect of the drugs. The combinations used in the isobole were: monensin 
1μM: podophyllotoxin 15nM, monensin 1μM; podophyllotoxin 30nM and monensin 2μM; 
podophyllotoxin 30nM. As mentioned in section 2.4.4, combination data points that fall on the line 
represent an additive interaction, whereas points above or below represent antagonism or synergy, 
respectively. In addition, points that are in close proximity to the line are also considered as having an 
additive interaction. Significantly, the isobologram analysis predicted the drugs to have an additive 























Figure 20. Dose dependent response of DU145 prostate cancer cells to monensin treatment. 
MTT proliferation assay of monensin and 0.1% DMSO 48 hours post treatment. Data shown are 
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Figure 22. Combinatorial effect of monensin and podophyllotoxin on DU145 prostate cancer 
cell line proliferation. MTT proliferation assay was performed 48 hours post treatment with 
mono and combination therapy, 0.1% DMSO control. Data shown are mean±s.d. of triplicate 
independent experiments.  OD, absorbance. p<0.001 
Figure 21. Dose dependent response of DU145 prostate cancer cells to podophyllotoxin 
treatment. MTT proliferation assay of podophyllotoxin and 0.1% DMSO 48 hours post treatment. 


















Figure 23. Isobologram analysis of the combinatorial effect of monensin and podophyllotoxin. 
All three points representing a dose dependent effect on proliferation lie close to the linear isobole 
(line of additivity) indicating that the drugs have an additive effect on each other’s drug activity. 
Cross (1:15) represents monensin 1μM: podophyllotoxin 15nM, plus sign (1:30) monensin 1μM: 
podophyllotoxin 30nM and the circle (1:15) represents monensin 2μM: podophyllotoxin 30nM.  
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Chapter 4: Discussion 
Molecular target based treatment of PCa is an evolving approach to PCa therapy. Although initially 
targeted at androgen deprivation therapy (ADT) due to the dependence of PCa tumours on androgens 
for growth, the emergence of androgen independent tumours has narrowed the scope of activity of 
these drugs. In addition, the close correlation between this mode of treatment and depletion in male 
sexual functioning has made ADT undesirable. Therefore, alternative protein targets have become 
essential and are currently being tested at clinical trials for anti-PCa activity. Inhibition of protein 
degradation has been one of the pathways that have emerged as potentially effective in cancer 
treatment with minimal adverse effects. In the course of this study we have identified DCUN1D1, a 
neddylation E3 ligase, as a potential new drug target for PCa treatment.  
DCUN1D1 has been reported to be upregulated in several squamous cell carcinomas, particularly 
head and neck, lung, cervical and ovarian cancer (Sarkaria et al., 2004; Sarkaria et al., 2006). It has 
also been associated with an aggressive phenotype and poor clinical outcomes in these cancers 
(Sarkaria et al., 2006). In addition, DCUN1D1 expression has been correlated with the T classification 
in non small cell lung carcinomas where high DCUN1D1 expression was linked to late stages of the 
disease but interestingly, DCUN1D1was observed to be a marker for brain metastasis (Yoo et al., 
2012). Additionally, DCUN1D1 is reported to result in tumour formation and malignant 
transformation in gliomas in vivo (Broderick et al., 2010).  In this study, we observed DCUN1D1 
mRNA and protein to be upregulated in PCa, which has not been described previously. Additionally, 
we demonstrate DCUN1D1 to be relevant for human tissue samples where in a panel of 
adenocarcinoma of the prostate stages I, II and III, BPH, normal tissue and other disease controls, 
DCUN1D1 was upregulated relative to normal prostate tissue with increased levels observed in 42% 
of the cancer samples. We also observed this following immunohistochemistry analysis of a separate 
group of human tissue samples where 43.7% showed high expression of DCUN1D1. We could not 
extrapolate the exact relationship between DCUN1D1 and adenocarcinoma stages from the tissue 
array or the immunohistochemistry analysis. However, we have demonstrated that DCUN1D1 is 
essential for PCa. 
In order to determine how DCUN1D1 contributes to PCa tumourigenesis we evaluated its effect on 
proliferation, migration and apoptosis. DCUN1D1 overexpression has been described to induce 
malignant transformation and proliferation of cells as well as to induce tumour formation in xenograft 
mice models (Sarkaria et al., 2006). It has also been implicated in several hallmarks of cancer 
including increased proliferation, migration, invasion, angiogenesis and inhibition of apoptosis 
(Sarkaria et al., 2004; Sarkaria et al., 2006; O-charoenrat et al., 2008; Broderick et al., 2010).We have 
demonstrated that in PCa, blockage of DCUN1D1 inhibits tumour growth in MF1 nude mice with a 
58% reduction in tumour weight observed. In addition, our data clearly indicates that upon inhibition 
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of DCUN1D1, PCa cells lose their ability to proliferate and migrate and they undergo an induction of 
apoptosis. Although apoptosis was not induced at the levels that we would expect, it is possible that 
other mechanisms of cell death are responsible for DCUN1D1 activity in prostate cancer such as 
autophagy. However, DCUN1D1 clearly functions as an oncogene in PCa and a dysregulation in its 
expression is detrimental to the cancer.  
We have demonstrated the individual hallmarks of cancer that DCUN1D1 is implicated in above, 
however our microarray analysis suggests the broader mechanism behind DCUN1D1 activity in PCa. 
Blockage of DCUN1D1 may be deregulating key functions and pathways associated with 
tumourigenesis mainly through developmental pathways. As observed previously in primary lung, 
head and neck and cervical carcinomas, DCUN1D1 appears to play a role in developmental pathways 
(Sarkaria et al., 2006). Of the top 10 functions that could be deregulated following DCUN1D1 
knockdown in DU145 PCa cells, 6 were associated with development. This may be significant as 
DCUN1D1 was previously demonstrated to play a role in the embryonic development pathway, 
hedgehog signalling, in SCC (Sarkariaet al., 2006). Additionally, two E2 ubiquitin conjugating 
enzymes, UBE2C and UBE2J2, were also deregulated which suggests the effects of DCUN1D1 
knockdown on ubiquitination. Although these two genes are associated with ubiquitination, it was not 
possible within the scope of this study to conclude the functionality of these E2s in association with 
DCUN1D1 neddylation. However, UBE2C has been implicated in cell cycle regulation through UPP-
mediated degradation of cyclin B while UBE2J2 has been implicated in endoplasmic reticulum 
associated degradation and could therefore be contributing to the changes in cell cycle and regulation 
of protein expression observed following DCUN1D1 knockdown (Townsley et al., 1997; Oh et al., 
2006). However, the transcription level effects of DCUN1D1 on particular genes involved in 
ubiquitination, PCa development, gene expression, cellular growth and proliferation pathways and 
cell death, as suggested by the microarray analysis, needs to be validated by further in vitro analysis 
but was not within the scope of this study. We have instead identified structurally and mechanistically 
distinct drugs that may affect DCUN1D1 expression using the connectivity map approach. 
As mentioned previously, we used the connectivity database (cmap) in order to identify DCUN1D1 
specific inhibitors of PCa. This is a novel approach which was developed by the Broad Institute of 
MIT and Harvard in Cambridge and allowed us to use comparisons of gene expression signatures to 
link PCa and potential inhibitors of PCa. The approach proved to be successful because of the 30 
drugs that we screened, 7 significantly altered DCUN1D1 mRNA (anisomycin, monensin, lasalocid, 
podophyllotoxin, thapsigargin, lycorine and vinblastine) while 11 altered its protein expression (all 
except for guanabenz). Although we were interested only in the drugs leading to a significant 
reduction in DCUN1D1 mRNA and protein expression, the number of drugs altering DCUN1D1 
expression means that the theoretical predictions made by the cmap database were relatively accurate 
and we were able to identify the desired drugs. Significantly, we were able to identify monensin and 
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podophyllotoxin as compounds mediating PCa inhibition through DCUN1D1 and these were chosen 
for combinatorial analysis. Additionally, because these drugs are already approved by the US FDA, it 
means that if evaluations in animal models are successful, these drugs could be approved for use in 
PCa treatment. We discuss the details of the drugs and their possible mechanisms of activity below. 
Of the 30 drugs evaluated in our study, 9 were antibiotics, 4 were plant derivatives and 9 were 
inhibitors of neurotransmitter receptors. We also identified a SERCAs inhibitor, an amino acid and 
nucleotide metabolisms synthesis regulator, an ion channel inhibitor, a bile acid, an inhibitor of 
phosphoglycerate kinase and phosphoglyceromutase and a testosterone metabolite. Following initial 
screening of the compounds which we identified through the cmap database, 12 drugs (anisomycin, 
monensin, lasalocid, podophyllotoxin, thapsigargin, lycorine, vinblastine, econazole, eticlopride, 
cyclobenzaprine, guanabenz and biperiden) were identified as significantly inhibiting PCa 
proliferation. In depth analysis of the structure and mechanism of activation of the drugs identified in 
our cmap analysis revealed interesting information. Although all of the drugs appear to have large 
hydrophobic groups, there does not appear to be any other striking similarity in the structure of these 
drugs. However, some have similar cellular activity. Monensin, lasalocid and thapsigragin are all 




exchange and calcium signalling, respectively 
(Bains, 1980; Russell, 1987; Kovacs et al., 2005). In addition, guanabenz, cyclobenzaprine, 
eticlopride and biperiden are neurotransmitter inhibitors. Guanabenz is an adrenergic receptor agonist 
(Misu & Fujie, 1982), cyclobenzaprine, a 5HT2 serotonin receptor antagonist (Brioschi et al., 2013); 
eticlopride targets the dopamine D2 receptor (Giuliani & Ferrari, 1997), while biperiden is a 
muscarinic acetylcholine receptor (Eltze, 1988). Anisomycin and lycorine have been described to 
inhibit protein synthesis while vinblastine and podophyllotxin inhibit microtubule assembly by 
inhibition of tubulin polymerization (Grollman, 1967; Vrijsen et al., 1986; Toso et al., 1993; Imbert, 
1998). As described in chapter 1 of this study, PI3K/AKT, MAPK are pathways that heavily involved 
in PCa signalling and have been associated with PCa proliferation and survival. Lasalocid, biperiden, 
cyclobenzaprine, eticlopride, anisomycin, guanabenz, econazole have been described to mediate their 
activity through inhibition of either both or one of these pathways (Kinsel et al., 1982; Tennant, 1984; 
Eltze, 1988; Giuliani & Ferrari, 1997; Jan et al., 1999; Stadheim & Kucera, 2002; Brioschi et al., 
2013).   
However, 9 of these drugs (anisomycin, monensin, lasalocid, podophyllotoxin, thapsigargin, 
econazole, biperiden, eticlopride and cyclobenzaprine) displayed inhibition of proliferation that was 
dependent on DCUN1D1 expression. These drugs also showed minimal toxicity in normal prostate 
cells (PNT1A) which suggests that they could be tolerated in humans. In addition, monensin, 
podophyllotoxin, biperiden, eticlopride and guanabenz treatment led to a significant induction of 
apoptosis. However, treatment with lasalocid, monensin and podophyllotoxin decreased DCUN1D1 
mRNA, while anisomycin and lycorine increased DCUN1D1 expression. A subsequent decrease in 
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DCUN1D1 protein expression was observed following treatment with monensin and podophyllotoxin 
with reductions also observed following treatment with anisomycin, lycorine and vinblastine. 
Therefore the connectivity map was useful in identifying small molecules that could mediate 
DCUN1D1-dependent anti-PCa activity. Based on the screening approach set for this study, the drugs 
that significantly inhibit PCa growth with a subsequent induction of cell death that was mediated 
specifically through reduction of DCUN1D1 mRNA and protein were monensin and podophyllotoxin. 
We excluded the drugs that increased DCUN1D1 mRNA or protein as our data indicates that 
DCUN1D1 is an oncogene in PCa and because its mechanism of action is still unclear. However, it is 
important to mention that the drugs increasing DCUN1D1 expression could be taking advantage of its 
role in protein degradation and therefore inhibiting proliferation and inducing apoptosis by increased 
degradation of crucial cellular proteins. Monensin and podophyllotoxin met the criteria of our 
screening process and were chosen for further analysis on PCa cell proliferation. Varying 
concentrations of both drugs were used followed by isobologram analysis demonstrating the drugs to 
have an additive effect on the inhibition of PCa proliferation. 
We identified monensin and podophyllotoxin as DCUN1D1-specific inhibitors of PCa with an 
additive inhibitory effect and we explore the possible mechanism behind this activity.  Monensin is a 




transport while podophyllotoxin inhibits tubulin 
polymerization (Russell, 1987; Imbert, 1998). Previous studies have demonstrated monensin to have a 
wide spectrum of activity but significantly it is a potent anticancer drug. It has been reported to induce 
cell cycle arrest, oxidative stress and apoptosis in PCa cells (Ketola et al., 2010). Podophyllotoxin on 
the other hand is known mainly for its antiviral activity in the treatment of genital warts but its ability 
to inhibit tubulin polymerisation have also made it a strong anti-cancer drug (Jordan et al., 1992; 
Strand et al., 1995; Imbert, 1998). In terms of this study, firstly, analysis of the microarray data 
suggests that axonal guidance and semaphorin signalling, are dysregulated following DCUN1D1 and 
these pathways have been reported to be dependent on endocytosis. In addition, among the predicted 
top 10 up and downregulated genes, many genes are associated with endocytosis and lysosomal 
degradation. Interestingly, monensin has been reported to mediate its activity through prevention of 
endosomal activity and disruption of Golgi apparatus activity while podophyllotoxin inhibits tubulin 
polymerization (Berg et al., 1983; Imbert, 1998). Endocytosis and lysosomal degradation have 
previously been associated with PCa development. The acidic pH of intracellular tumour environment 




activity which leads to increased proton expulsion and subsequently 
contributes to the acidic extracellular pH observed in PCa tumour extracellular microenvironments 
(Steffan et al., 2009). Increased extracellular acidity has been shown to lead to peripheral trafficking 
of lysosomal vesicles and release of proteases which act under acidic conditions and improve the 
invasive capacity of tumour cells (Steffan et al., 2010). In addition, the current chemotherapeutic 
agent used in PCa treatment, docetaxel, has been shown to induce lysosomal permebealization in its 
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anti-PCa activity (Mediavilla-Varela et al., 2009). Therefore, since these endosomal and lysosomal 
vesicles are transported along the cytoskeleton and depend on intact tubulin it is likely that monensin 
and podophyllotoxin are mediating their activity by altering the extracellular microenvironment and 
disrupting the tubulin network necessary for vesicular transport. They probably target DCUN1D1 to 
alter these pathways through disruptions in neddylation.  
DCUN1D1 is an E3 ligase for the neddylation pathway and alterations in its expression have been 
reported to alter cullin neddylation. However, as mentioned previously, cullins are not the only 
substrates of NEDD8. Some of proteins that have been identified as NEDD8 substrates include 
EGFR, pVHL and BCA3 (Stickle et al., 2004; Gao et al., 2006; Oved et al., 2006). EGFR has been 
demonstrated to undergo mono and multi-neddylation prior to endocytic degradation, (Oved et al., 
2006). Endocytosis is a process which involves internalization of large polar molecules through 
engulfment (Doherty & McMahon, 2009). The most extensively described endocytosis pathway is the 
clathrin coat-mediated endocytosis where clathrin coated pits from the cellular membrane detach from 
the plasma membrane to form clathrin-coated vesicles (Robinson, 1994). These vesicles then mediate 
early and late endocytosis which leads to lysosomal degradation or recycling of the engulfed 
molecules. Therefore elevated DCUN1D1 levels could suggest increased NEDD8 conjugation to 
proteins such EGFR and endosomal-lysosomal degradation of these proteins. Additionally, monensin 
which has been reported to inhibit particularly intracellular degradation of proteins internalized into 
the endosome and not inhibition of protein internalization into the endosome could be targeting 
DCUN1D1 to inhibit protein degradation, however this would need to be validated. In addition, 
neddylation has been described to mediate fibronectin assembly through pVHL neddylation therefore 
podophyllotoxin could be targeting inhibition of DCUN1D1-mediated neddylation for cytoskeleton 
disruption (Stickle et al., 2004). Lastly, other NEDD8 substrates that have been characterized include 
p53, Mdm2 and BCA3 which recruits SIRT1 to NF-κB (Stickle et al., 2004; Gao et al., 2006). 
Therefore, inhibition of DCUN1D1 through deregulation of neddylation could be affecting key genes 
in PCa which could explain its role in PCa and its anti-cancer activity.  
In addition, the pathways identified in here as deregulated following DCUN1D1 blockage have been 
characterized as key pathways of PCa development and progression in other studies. Analysis of three 
studies done recently (Wang et al., 2011; Li et al., 2013; Wen et al., 2013) employing bioinformatics 
to identify pathways essential for PCa development revealed interesting similarities to our study. Two 
of these studies used gene expression data from microarray analysis available in the public database 
GEO (Gene Expression Omnibus) and compared gene signatures between normal and tumour prostate 
tissue. The authors then used the gene signatures to identify small molecules that could be used to 
target PCa treatment. The pathways identified as deregulated were similar to those observed in our 
study where they observed alterations in cell cycle regulation, Wnt/β-catenin signalling, focal 
adhesion and actin skeleton regulation. (See Appendices Table A3 and A4). Therefore, not only have 
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we demonstrated DCUN1D1 to be essential for PCa progression but we have demonstrated that 
deregulation of DCUN1D1 affects pathways established to be essential in human tissue samples as 
crucial for PCa development. However, DCUN1D1 is a unique protein due to its link to neddylation 
and it offers a new and more specific approach to targeting these pathways for PCa inhibition.  
As mentioned previously, inhibition of protein degradation pathways is an emerging approach to 
small molecule based treatment of cancer. Bortezomib and MLN4924 are two drugs that have been 
identified as chemotherapeutic agents against a wide variety of malignancies and they have proven the 
efficacy of inhibition of protein degradation as an approach to cancer treatment. Having established 
the significance of DCUN1D1 in PCa and preliminarily identified small molecule inhibitors of 
DCUN1D1, our view is that DCUN1D1 is likely a new target for PCa treatment. The signalling 
pathways and mechanisms of activity of the small molecules used in this study suggest that inhibition 
of DCUN1D1 is able to reverse PCa gene expression profiles likely due to its role as an E3 ligase in 
the neddylation pathway, downstream of the NAE currently targeted by MLN4924. Thus targeting 


















Chapter 5: Conclusion 
DCUN1D1 or SCCRO is an under explored protein. Although previous studies have demonstrated it 
to be upregulated in tumours of squamous origin, we have clearly demonstrated that it plays a key role 
in solid PCa tumour growth. We have provided in vitro and in vivo analyses which have demonstrated 
the pivotal role of DCUN1D1 on PCa tumourigenesis. We also demonstrated that DCUN1D1 could 
be mediating its activity through deregulation of essential cell growth, proliferation, development, 
gene expression and cancer-related pathways. In addition, we have demonstrated the potential of 
DCUN1D1 as a novel drug target for PCa treatment through the identification of monensin and 
podophyllotoxin as DCUN1D1 specific inhibitors of PCa growth.  It is possible that they are targeting 
DCUN1D1-mediated neddylation for endosomal-lysosomal degradation and microtubule disruptions. 
Since these drugs are currently approved by the US FDA for use in different disease, following the 
necessary characterization, they could get approval for use in PCa. 
In conclusion, DCUN1D1 is essential for PCa growth and has the potential to be a new therapeutic 

















Chapter 6: Areas of further research 
In this study we employed a genomics approach to understanding the role of DCUN1D1 in PCa but 
due to the role of DCUN1D1 in protein modification, it would be essential to determine its role at the 
protein level. This would require proteomics analysis with an emphasis on identifying direct and 
indirect protein binding targets of DCUN1D1 but also proteins targeted by DCUN1D1 for 
neddylation. The role of DCUN1D1 activity in PCa would also need to be evaluated. Although there 
is significant evidence that alterations in DCUN1D1 expression are detrimental to PCa, in vitro and in 
vivo neddylation assays would need to be performed to determine if DCUN1D1 activity is altered. In 
addition, the exact mechanism of DCUN1D1 activity under physiological and cancer conditions needs 
to be elucidated. The neddylation pathway plays a pivotal role in mediating ubiquitination of proteins 
and regulation of numerous biological processes including cancer. In this context our group recently 
published a review paper where we discussed neddylation substrates which are deregulated in cancer 
as well as therapeutic approaches to targeting neddylation and our view is that DCUN1D1 could be a 
key target in cancer therapy (See Appendix 8.6). Its primary role, as described to date, has been 
through cullin neddylation and ubiquitination as a downstream effector but the mechanisms of action 
of the drugs found to be specific for DCUN1D1 in this study which include disruption of endocytosis 
and inhibition of microtubule function suggest that there is a lot to be learnt about DCUN1D1 and the 
neddylation pathway in general.   
Consequently, monensin and podophyllotoxin which were identified in the study as small molecule 
DCUN1D1 inhibitors of PCa would have to be evaluated further. Determinations need to be made on 
the best concentrations of these drugs to be used in mono and combination therapy, with these 
concentrations tested for in vivo activity. In vivo cytotoxicity of the two drugs used in combination 
would have to be evaluated.  The mechanism of action of these drugs on PCa would also need to be 
extensively analysed. This study has revealed a dependence of these drugs on DCUN1D1 and the 
extent of this dependence would have to be established. Significantly, since the current 
chemotherapeutic agent against PCa, docetaxel, has been described to mediate cell death in PCa cells 
through lysosomal membrane permeabilization, combination therapy with the drugs identified in this 
study should be explored. The proposed role of these drugs on DCUN1D1-neddylation mediated 
endocytosis could prove additive to the activity of docetaxel and thus improve the activity of this drug 
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Chapter 8: Appendix 
8.1 Table A1: Top 50 genes upregulated following DCUN1D1 knockdown in DU145 cell lines in 
descending order. 
 Gene Description Fold 
change 
1 ATP6AP2 ATPase, H+ transporting, lysosomal accessory protein 2 19.97 
2 EEF2 Eukaryotic translation elongation factor 2 6.3 
3 UBE2C Ubiquitin-conjugating enzyme E2C 5.9 
4 SPTBN1 spectrin, beta, non-erythrocytic 1 4.4 
5 BAT2D1 BAT2 domain containing 1 4.04 
6 TNPO1 Transportin 1 3.85 
7 SF3B1 Splicing factor 3b, subunit 1, 155kDa 3.68 
8 CADM1 Cell adhesion molecule 1 3.59 
9 SH3GLB1 SH3-domain GRB2-like endophilin B1 3.48 
10 HAX1 HCLS1 associated protein X-1 3.24 
11 TXNL1 Thioredoxin-like 1 3.19 
12 HUWE1 HECT, UBA and WWE domain containing 1 3.11 
13 EIF3A Eukaryotic translation initiation factor 3, subunit A 3.02 
14 TCF4 Transcription factor 4 3 
15 C11orf31 Chromosome 11 open reading frame 31 2.98 
16 FUNDC2 FUN14 domain containing 2 2.9 
17 TNPO1 Transportin 1 2.86 
18 AKIRIN2 Akirin 2 2.86 
19 CHORDC1 Cysteine and histidine-rich domain (CHORD)-containing 1 2.8 
20 PTPN12 Protein tyrosine phosphatase, non-receptor type 12 2.69 
21 HBS1L HBS1-like (S. cerevisiae) 2.69 
22 STAG2 Stromal antigen 2 2.64 
23 FLOT1 Flotillin 1 2.62 
24 HEATR2 HEAT repeat containing 2 2.58 
25 MAGED1 Melanoma antigen family D, 1 2.56 
26 DNAJC21 DnaJ (Hsp40) homolog, subfamily C, member 21 2.54 
27 SON SON DNA binding protein 2.49 
28 TRIP12 Thyroid hormone receptor interactor 12 2.48 
29 NUP205 Nucleoporin 205kDa 2.44 
30 SHOX2 Short stature homeobox 2 2.44 
31 HNRNPL Heterogeneous nuclear ribonucleoprotein L 2.42 




33 SPTBN1 Spectrin, beta, non-erythrocytic 1 2.36 
34 RPS3A Ribosomal protein S3A 2.33 
35 AKR1A1 Aldo-keto reductase family 1, member A1 (aldehyde 
reductase) 
2.31 
36 PUM1 Pumilio homolog 1 (Drosophila) 2.31 
37 APP Amyloid beta (A4) precursor protein              2.3 
38 PTCRA Pre T-cell antigen receptor alpha 2.3 
39 ITCH Itchy E3 ubiquitin protein ligase homolog (mouse) 2.29 
40 ATXN2 Ataxin 2 2.27 
41 EXOSC2 Exosome component 2 2.25 
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8.2 Table A2: Top 50 genes downregulated following DCUN1D1 knockdown in DU145 cell lines 
in descending order. 
42 GPHN Gephyrin 2.24 
43 PRMT5 Protein arginine methyltransferase 5 2.24 
44 PHACTR4 Phosphatase and actin regulator 4 2.23 
45 KDELR1 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein 
retention receptor 1 
2.23 
46 CREBBP CREB binding protein 2.22 
47 CWC15 CWC15 spliceosome-associated protein homolog (S. 
cerevisiae) 
2.19 
48 RPP30 Ribonuclease P/MRP 30kDa subunit 2.18 
49 EZR Ezrin 2.18 
50 NCOA1 Nuclear receptor coactivator 1 2.17 
 Gene Description Fold 
change 
1 UBE2J2 Ubiquitin-conjugating enzyme E2, J2 (UBC6 homolog, 
yeast) 
-9.5 
2 BAT2 HLA-B associated transcript 2 -8.46 
3 ZFPM1 Zinc finger protein, multitype 1 -6.97 
4 CLDN6 Claudin 6 -6.73 
5 TNPO2 Transportin 2 -6.4 
6 NMNAT3 Nicotinamide nucleotide adenylyltransferase 3 -5.93 
7 EPHB4 EPH receptor B4 -5.38 
8 ACAA2 Acetyl-Coenzyme A acyltransferase 2 -5.36 
9 ACAD10 Acyl-Coenzyme A dehydrogenase family, member 10 -5.04 
10 FAM109A Family with sequence similarity 109, member A -5.01 
11 PI16 Peptidase inhibitor 16 -4.86 
12 MRC2 Mannose receptor, C type 2 -4.7 
13 SLC6A2 Solute carrier family 6 (neurotransmitter transporter, 
noradrenalin), member 2 
-4.67 
14 ODF3B Outer dense fiber of sperm tails 3B -4.55 
15 DOHH Deoxyhypusine hydroxylase/monooxygenase -4.31 
16 ZNF696 Zinc finger protein 696 -4.11 
17 MYL10 Myosin, light chain 10, regulatory -4.11 
18 SARDH Sarcosine dehydrogenase -4.09 
19 C11orf30 Chromosome 11 open reading frame 30 -4.08 
20 SFN Stratifin -4.04 
21 HKDC1 Hexokinase domain containing 1 -4 
22 SMOX Spermine oxidase -3.99 
23 COL1A1 Collagen, type I, alpha 1 -2.53 
24 CASR Calcium-sensing receptor -3.94 
25 TMEM184A Transmembrane protein 184A -3.84 
26 TTLL3 Tubulin tyrosine ligase-like family, member 3 -3.82 
27 AP2A1 Adaptor-related protein complex 2, alpha 1 subunit -3.81 
28 DLG4 Discs, large homolog 4 (Drosophila) -3.8 
29 FGF18 Fibroblast growth factor 18 -3.78 
30 HAB1 B1 for mucin -3.76 
31 TRABD TraB domain containing -3.68 
32 PSD Pleckstrin and Sec7 domain containing -3.63 









34 EPS15L1 Epidermal growth factor receptor pathway substrate 15-like 
1 
-3.52 
35 TEAD2 TEA domain family member 2 -3.5 
36 SNX26 Sorting nexin 26 -3.48 
37 MEX3A Mex-3 homolog A (C. elegans) -3.46 
38 BRD4 Bromodomain containing 4 -3.43 
39 SIK1 Salt-inducible kinase 1 -3.4 
40 CNTROB Centrobin, centrosomal BRCA2 interacting protein -3.36 
41 FMN2 Formin-2 -3.3 
42 JSRP1 Junctional sarcoplasmic reticulum protein 1 -3.27 
43 HMGB2 High-mobility group box 2 -3.26 
44 MAPRE3 Microtubule-associated protein, RP/EB family, member 3 -3.23 
45 TOMM40 Translocase of outer mitochondrial membrane 40 homolog 
(yeast) 
-3.21 
46 FAM83G Family with sequence similarity 83, member G -3.19 
47 MORN1 MORN repeat containing 1 -3.17 
48 WTIP Wilms tumor 1 interacting protein -3.16 
49 HDAC10 Histone deacetylase 10 -3.13 
50 TFRC Transferrin receptor (p90, CD71) -3.13 
Pathway Current study (Wen et al., 2013) (Li et al., 2013) 
1 Axonal guidance 
signalling 
Spliceosome Focal Adhesion  
2 PKA Signalling DNA replication TGF-β signalling Pathway  
3 Molecular mechanisms 
of cancer 
Cell cycle MAPK signalling pathway  
4 TR/RXR activation Focal adhesion Regulation of actin cytoskeleton  
5 Cyclins & Cell cycle 
regulation 
ECM receptor MicroRNAs in cardiomyocyte hypertrophy  




Wnt signaling pathway and pluripotency 
7 WNT/β-catenin 
signaling 
Pyrimidine metabolism EGF/EGFR signaling Pathway  
8 Cell cycle G1/S 
checkpoint regulation 
Cell adhesion molecules 
(CAMs) 
Apoptosis  






10 MODY Signaling Ribosome Endochondral Ossification 
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8.4 Table A4: Comparison of functions altered in the current study and following wide spread 













Function Current study Wang et al., 2011) 
1 Gene expression Development  
2 Cellular growth & proliferation Signal transduction 
3 Cellular development Apoptosis  
4 Tissue development Survival 
5 Organismal development Cytoskeleton remodelling 
6 Cell death Transcription 
7 Skeletal & muscular system 
development and function 
 
8 Embryonic development  
9 Organ development   
10 Cancer  
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The appropriate balance of intracellular protein 
levels is essential for many cellular processes 
including the cell cycle and the regulation of 
gene expression. While protein synthesis is a 
relatively slow process, protein degradation pro-
vides a rapid and irreversible switch-like activity 
that shuts off key regulatory proteins.
One major pathway for protein degradation 
is the ATP-dependent three-step process of pro-
tein modification with long polyubiquitin chains 
made up of multiple ubiquitin monomers, with 
the ultimate aim to target proteins for recogni-
tion and processing by the 26S proteasome – a 
multiprotein complex containing four stacked 
rings with each ring composed of seven subunits, 
which is responsible for the ATP-dependent 
degradation of ubiquitin-tagged proteins [1]. 
Recently, the ubiquitin-like protein NEDD8 has 
been identified that similarly targets proteins 
for degradation via the neddylation pathway as 
described later in this review. As neddylation 
and ubiquitination strongly effect one another, 
the first part of this review will focus on the 
 well-studied ubiquitination pathway.
The other major route for intracellular pro-
tein degradation, autophagy, has recently been 
reported to display active cross-talk with prote-
asome-mediated degradation [2,3]. While it has 
been suggested that certain substrates can be tar-
geted by ubiquitylation for degradation via both 
systems, perturbations in the flux through either 
pathway has been reported to affect the activity of 
the other system [3]. The effect of this cross-talk 
with regard to tumorigenesis is best illustrated by 
the most common genetic target in human can-
cers, the tumor suppressor gene p53; inhibition 
of autophagy was reported to lead to impaired 
proteasome-mediated p53 degradation, which in 
turn may predispose cells to apoptosis [3].
The ubiquitination pathway begins with the 
activation of ubiquitin by E1 (also known as 
the ubiquitin-activating enzyme) in an ATP-
dependent manner [4,5]. The ubiquitin-activating 
enzyme is the E1 that is thought to primarily per-
form this function; however, recently a relatively 
uncharacterized E1 enzyme, Uba6, was found to 
also activate ubiquitin [6]. The E1 enzyme then 
transfers the activated ubiquitin molecule to the 
cysteine residue of the E2-conjugating enzyme 
[7,8]. Several E2-conjugating enzymes have been 
identified so far with 35 active E2s already iden-
tified in humans. This increase in the number 
of E2s relative to the known E1s is suggested to 
account for substrate specificity in that distinct 
primary sequences within the core domains of 
E2s can specify cognate E3s, substrate specificity 
and localization [9]. The E3 ligases then form 
the final step in the cascade by facilitating the 
transfer of ubiquitin from E2 to the substrate [10]. 
Several hundred different E3 ligases have been 
identified that display substrate specificity and 
have been grouped into three classes based on 
the domain found in their core proteins. These 
include the HECT (homologous to E6-AP car-
boxy terminus), RING (really interesting new 
gene) and U-box E3 ligases [11–13]. Of particular 
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The neddylation conjugation pathway has a pivotal role in mediating 
ubiquitination of proteins and regulation of numerous biological processes. 
Dysregulation in the ubiquitination and neddylation pathways is associated with 
many cancers. Ubiquitination involves covalent attachment of ubiquitin to target 
proteins, leading to protein degradation by the proteasome system. The activity 
of the E3-ubiquitin ligase family, cullin-RING ligases, is essential for promoting 
ubiquitin transfer to the appropriate substrates. Neddylation, a process mediated 
by the protein NEDD8, is required for conformational changes of cullins, a 
scaffolding protein situated in the core of cullin-RING ligases, and regulation of 
E3 ligase activity. In this review, we present a comprehensive discussion of the 
recent findings on the neddylation pathway and its importance during 
tumorigenesis. The ramifications regarding the potential therapeutic use of 
ubiquination and neddylation inhibition are also discussed.
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interest in this review are the cullin-RING E3 
ligases that are multicomponent complexes con-
sisting of the RING finger domain-containing 
protein RBX1/2, a cullin protein that acts as a 
scaffolding molecule, and other adaptor proteins 
and substrate-binding sites [14]. The basic func-
tion of all the E3 ligases is to recognize specific 
substrates and to provide optimal conditions for 
ubiquitin transfer from E2-conjugating enzymes 
to the substrate.
Targets for the ubiquitin-dependent 
mechanisms in cancer
Ubiquitination plays a central role in cellular 
homeostasis and particularly in regulating the 
cell cycle by targeting and destroying regula-
tory proteins. Several malignancies and certain 
oncogenic viral infections are characterized by 
alterations of the ubiquitin–proteasome path-
way, thereby disrupting the ubiquitination of 
proteins that control cell growth and death, lead-
ing to the deregulation of the cell cycle, specifi-
cally the G1 phase control and progression to 
S phase [15]. The development of cancer can be 
due to the stabilization of oncoproteins or the 
destabilization of tumor suppressor genes. For 
example, the tumor suppressor gene p53 has long 
been known to be degraded by the ubiquitin–
proteasome pathway after infection with high-
risk oncogenic HPV types [16]. Also, p53 is inac-
tivated in a variety of cancers due to oncogenic 
activation and/or overexpression of its specific 
E3-ubiquitin ligase MDM2 [17]. Another well-
known tumor suppressor protein associated with 
susceptibility to breast cancer is BRCA1, which 
harbors E3-ubiquitin ligase activity. When 
mutated, intermolecular interactions of BRCA1 
with target proteins are affected, thus leading to 
predisposition to malignancies [18]. In renal cell 
carcinoma it was found that oncogenic muta-
tions in components of the E3-ubiquitin ligase 
complex prevents degradation of the HIF1 tran-
scription factor, resulting in its upregulation and 
predisposition to the formation of renal tumors 
[19]. High expression of the E3-ubiquitin ligase 
Smurf2 was found to correlate with poor prog-
nosis in esophageal squamous cell carcinoma 
as this enzyme interferes with members of and 
inactivates the TGF-b signaling pathway [20]. 
Significant adverse impacts on the survival of 
esophageal squamous cell carcinoma patients 
was demonstrated by downregulation of the 
ubiquitin ligase FBXW7, which normally targets 
positive cell cycle regulators [21]. In colonic car-
cinoma, the tumor suppressor gene APC is often 
found as a truncated form that is no longer able 
to regulate cellular levels of b-catenin. Under nor-
mal conditions this protein is tightly controlled 
by the cellular machinery and targeted for ubiq-
uitination and degradation as it can lead to the 
transcriptional activation of various oncogenes 
and cell cycle genes [22].
Therapeutic approaches for inhibition of 
ubiquitination in cancer
The aforementioned examples clearly dem-
onstrate the central role of the ubiquitin–pro-
teasome pathway for tumorigenesis. Therefore, 
protein degradation pathways via ubiquitina-
tion are potential targets for anticancer therapy. 
Many inhibitors have been tested and shown to 
inhibit either the proteasome or substrate-spe-
cific E3 ligases [23]. However, only a few drugs 
could be further developed in clinical trials as 
many have displayed poor metabolic stability, 
poor enzyme specificity, poor pharmacological 
effects and/or irreversible binding (and inhi-
bition) of the proteasomal subunit [23]. The 
dipeptide boronic acid analogue bortezomib 
(VELCADE® [Millenium Pharmaceuticals], 
formerly known as PS-341) has been found to 
be a metabolically stable, potent, specific and 
reversible proteasome inhibitor as it selectively 
inhibits malignant cell growth and induces 
apoptosis and kills tumor cells, particularly in 
B-cell malignancies [24,25]. Bortezomib was the 
first anticancer drug inhibiting the 26S protea-
some to be approved for single-agent use in the 
clinical treatment of patients with newly diag-
nosed multiple myeloma, relapsed/refractory 
multiple myeloma and mantle cell lymphoma 
[26,27]. In clinical trials it was found that bortezo-
mib was relatively well tolerated by the patients, 
producing efficacious clinical responses with a 
35% overall response rate and 10% complete 
responses [28]. This drug acts by forming a tran-
sition state intermediate with the enzymatically 
active chymotryptic site of the 20S core catalytic 
component of the proteasome [29]. Although this 
type of proteasome inhibition could theoreti-
cally disrupt many cellular processes, not only 
the proliferation of cancer cells, bortezomib 
was found to selectively inhibit malignant cell 
growth with some toxic effects on normal cells 
[30]. One explanation is that this drug interferes 
with the IkB/NF-kB regulatory system, a key 
characteristic of tumor development and pro-
gression [31]. In cancer cells, the transcription 
factor NF-kB is often constitutively expressed 
as its inhibitor IkB is degraded via the ubiqui-
tin–proteasome pathway, thereby leading to the 
uncontrolled activation of NF-kB anti-apoptotic 
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target genes. Bortezomib is thought to stabilize 
IkBa through proteasome inhibition, resulting 
in inhibition of NF-kB activation [29]. G2–M 
arrest, the upregulation of the pro-apoptotic pro-
tein NOXA as well as the stabilization of p53 
have also been discussed as possible mechanisms 
of bortezomib [32,33]. Despite its potent antican-
cer effects, over the years bortezomib has been 
shown to have some side effects, toxicities and 
resistance in individual patients. Several other 
proteasome inhibitors with improved properties 
are currently under clinical investigation such 
as carfilzomib and marizomib, which are still 
awaiting approval [26].
Rather than the inhibition of the protea-
some, which affects a wide range of proteins, 
the inhibition of substrate-specific ubiquitin E3 
ligases would represent potential therapeutic 
opportunities for targeted anticancer interven-
tion. Currently, various clinical trials are under-
way testing drugs with such effects, although 
none of them have been approved for clinical 
treatment as yet. One of the most promising 
E3-ubiquitin ligase inhibitors is the small mol-
ecule Nutlin-3 that prevents the interaction of 
MDM2 with its substrate p53, thus stabilizing 
the tumor suppressor protein [34].
Another therapeutic approach would be the 
stimulation rather than the inhibition of the 
ubiquitin–proteasome pathway for the selected 
degradation of proteins associated with human 
cancers. One such example is the targeted 
downregulation of growth factor receptors that 
are aberrantly activated in a variety of malig-
nancies. The drug trastuzumab (Herceptin®, 
Genentech), for example, is a monoclonal anti-
body against the growth factor receptor ErbB2. 
Binding of the antibody weakly activates ErbB2 
resulting in its homodimerization and recogni-
tion by the ubiquitin proteasome system, thus 
leading to its degradation [18]. Trastuzumab has 
been approved for use in patients whose tumors 
overexpress ErbB2 and has shown clinical activ-
ity alone and in combination with chemotherapy 
in metastatic breast cancer [35,36].
Neddylation: a pathway of ubiquitin-like 
protein conjugation
Ubiquitination is not the only process that regu-
lates the degradation of proteins. The ubiquitin-
like protein NEDD8 (the mammalian homo-
log of Rub1 protein in Saccharomyces cerevisiae) 
[37] is involved in neddylation, a modulator of 
ubiquitin-induced protein degradation. NEDD8 
is a small, highly conserved protein with 80% 
homology to ubiquitin. However, it has a very 
different conjugation pattern when compared 
with ubiquitin, and NEDD8-conjugated pro-
teins are highly expressed in the nucleus relative 
to the cytoplasm [38,39]. The neddylation pro-
cess involves the E1-activating enzyme complex, 
also known as the NEDD8-activating enzyme 
(NAE), composed of two subunits, APP-BP1 
and UBA3, and the E2-conjugating enzyme, 
UBC12 (also known as UBE2M). UBA3 is 
homologous to the C-terminal end of the E1 
enzyme involved in ubiquitination, whereas 
APP-BP1 is homologous to the N-terminus of 
the E1 protein [40]. UBC12 tethers selectively to 
NAE via a unique E1–E2-like interaction, and 
both the docking peptide and catalytic core 
domain of UBC12 must bind the NAE simul-
taneously for optimal transfer of NEDD8 from 
NAE to UBC12 (Figure 1) [41].
The most widely studied class of protein 
substrates of neddylation are the cullin-RING 
ligases (CRLs), which are anchored by cullins, a 
highly conserved family of proteins. The cullins 
Cul-1, Cul-2, Cul-3, Cul-4A, Cul-4B and Cul-5 
are all modified by NEDD8, which is conju-
gated to them via its C-terminal Gly-76 residue 
[39,42,43]. The SKP1–Cul-1–F-BOX (SCF) func-
tions as an E3 ligase for CRLs and consists of 
ROC1 (a small RING protein) bound to the 
C-terminus of Cul-1 and SKP1 bound to the 
N-terminus of Cul-1. ROC1 in turn binds to 
E2 and SKP1 can bind to a variety of F-BOX-
containing proteins. CAND1, a 120 kDa HEAT 
repeat protein, works as a negative regulator of 
SKP1–Cul binding, by preventing the binding 
of SKP1 and F-BOX proteins to cullins [44]. The 
crystal structure of the CAND1–Cul-1–ROC1 
complex shows that CAND1 clamps around the 
elongated Cul-1 [20]. Neddylation of the cullins 
dissociates CAND1, resulting in the assembly 
of an active ubiquitin ligase and subsequent 
substrate ubiquitination [42,44–46]. In this way, 
NEDD8 regulates the ubiquitination rate of 
the subset of proteins that are ubiquitinated via 
CRLs (Figure 2).
Therefore, the process of neddylation para-
llels that of ubiquitination. Each involves their 
own E1, E2, and E3 proteins in a chronological 
modification process in which small proteins 
need to be conjugated, activated and transferred 
to substrates.
The deneddylation of cullins is carried out by 
the COP9 signalosome (CSN). COP9 was first 
discovered as a novel protein complex consist-
ing of eight subunits, which negatively regulates 
photomorphogenesis in Arabidopsis thaliana [47]. 
It was later rediscovered in various mammalian 
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tissues [48,49], at which time it was renamed as 
the CSN complex, consisting of the subunits 
CSN1–CSN8, named according to their size 
[50]. The CSN is involved in various protein deg-
radation pathways. However, in deneddylation it 
serves to remove the NEDD8 protein from the 
CRL by cleaving NEDD8 from Cul-1 [51–53]. 
The Jab1/MPN domain metalloenzyme, found 
in the CSN5 subunit, underpins the NEDD8 
isopeptidase activity of the CSN [51]. The CSN 
binds to the SCF via CUL1 and ROC1, which 
interact specifically with subunits CSN2, CSN6 
and the N-terminus of CSN1 [52–54] (Figure 3). 
Another protein involved in deneddylation of 
NEDD8 is DEN1 [55,56], also known as NEDP1. 
DEN1 is a cysteine protease that demonstrates a 
60,000-fold preference for NEDD8 over ubiqui-
tin and acts as a NEDD8 isopeptidase by decon-
jugating NEDD8 from cullins [57,58]. If DEN1 
activity is increased, deneddylation of cullins is 
strongly affected and it may result in blocking 
degradation of ubiquitinated proteins with an 
impact on cell cycle progression. In this context, 
DEN1 has also been found to remove NEDD8 
from hyperneddylated cullins although not 
from mononeddylated cullins, maintaining the 
mononeddylated cullins levels necessary for the 
ubiquitination by SCF ubiquitin ligases [55,56]. 
However, DEN1 has an antagonistic role as it 
was shown to cleave off the C-terminal end of 
NEDD8, to form a mature NEDD8 molecule 
that is necessary for the neddylation process [59].
Targets for neddylation in cancer
Interestingly, it was recently shown that a vari-
ety of cellular stresses lead to a drastic increase 
in neddylation within the cell, which is medi-
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Figure 1. Schematic representation of ubiquitination and neddylation pathways.  
In ubiquitination (left-hand panel), E1-activating enzyme activates and transfers ubiquitin to E2 ligase 
via trans-thiolation reaction. The ubiquitin-charged E2 combines with specific E3 ligases in order to 
catalyze the formation of the polyubiquitin chain on the substrate protein, which will be recognized 
and degraded via the proteasome. Neddylation (right-hand panel) is initiated by an E1 enzyme 
specific to NEDD8 (NAE), which utilizes ATP to generate NEDD8 adenylate. NEDD8 is transferred to a 
specific cysteine within NAE, generating a NAE–NEDD8 thioester and transferred to specific E2 
ligases (such as UBC12 or UBE2F) via a trans-thiolation reaction. Finally, NEDD8 is transferred to a 
variety of E3 ligases such as the SKP1–Cul-1–F-BOX, which functions as an E3 ligase for cullin-RING 
ligases. The neddylation process also results in the assembly of an active ubiquitin ligase, assisting 
E3-catalyzed ubiquitylation and consequently substrate ubiquitination. 
NAE: NEDD8-activating enzyme.
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not NAE [60]. The most widely studied ned-
dylation targets include the CRLs, the EGF 
receptor and the E2F-1-transcription factor 
[61,62]. Very recently there have been a number 
of papers indicating that parkin and PINK1 
are involved in the neddylation cascade. Both 
proteins are involved in Parkinson’s disease 
[63,64]. Currently, the criteria by which proteins 
are chosen for the neddylation pathway is still 
unknown; however, many proteins involved 
in cancer progression have been identified as 
neddylation targets. One of these targets is 
the VHL protein. Mutations in VHL result 
in some rare familial cancer syndromes as well 
as the majority of sporadic renal cancers (as a 
result of bialleic loss of VHL) [65,66]. This is just 
one of many proteins that have been shown to 
play a role in cancer and are also involved in 
neddylation. In high-grade neuroendocrine 
lung tumors, a low level of CAND1, resulting 
in high levels of neddylated Cul-1, has been 
associated with disease [67]. Another example 
is SCCRO (also known as DCUN1D1), which 
forms part of the E3 ligase complex (Cul-1–
ROC1–SCCRO) for neddylation. SCCRO 
recruits the Ubc12–NEDD8 thioester to the 
neddylation E3 complex, thereby promoting 
cullin neddylation. In this way, SCCRO pro-
vides an additional level of regulation to the 
ubiquitination carried out by CRL-containing 
E3 complexes. Due to the wide range of pro-
teins regulated by CRL-containing E3s, it is 
not surprising that SCCRO has been impli-
cated in a variety of human cancers [68]. 
SCCRO, when overexpressed, is associated 
with an aggressive form of primary squamous 
cell carcinoma of the lung. Findings thus far 
























Figure 2. The regulation of cullin–RING ligases via CAND1 and NEDD8. CAND1 binds to the 
cullin–ROC1 complex blocking the SKP1 binding site. Mature NEDD8 then binds to the cullin–ROC1 
complex, displacing CAND1. SKP1 and F-BOX are now free to bind and recruit the substrate. E2 binds 
to the cullin–RING ligases complex via ROC1 and recruits ubiquitin to the substrate resulting in 












Figure 3. The deneddylation of target proteins via the COP9 signalosome. Once a protein 
substrate has been ubiquitinated, the SKP1–Cul-1–F-BOX complex is then deneddylated by the CSN. 
The CSN binds to the SKP1–Cul-1–F-BOX complex via the interaction between Cullin-1–ROC1 and via 
CSN2, CSN6 and the N-terminus of CSN1, the subunits within the CSN complex. The isopeptidase 
activity of the CSN results in the cleavage of Nedd8 from the cullin–RING ligases. This in turn allows 
the binding of CAND1, which displaces SKP1 and F-BOX, returning the cullin–RING ligases to the 
unneddylated form. 
CSN: COP9 signalosome.
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the transformation of cells and sustains the 
malignant cancer phenotype [69]. Mdm2 is 
well known to be involved in the ubiquitina-
tion and degradation of the tumor suppressor 
gene p53, as well as for its ability to act as an 
E3 ligase [70–72]. However, Mdm2 in its role as 
a RING finger E3-ubiquitin ligase is also ned-
dylated and promotes conjugation of NEDD8 
to p53. The critical cysteine C462 in the 
RING finger domain of Mdm2, required for 
its E3-ubiquitin ligase activity, is also required 
for Mdm2-dependent neddylation. It is inter-
esting to note that the lysine residues within 
Mdm2 that are required for Mdm2-mediated 
ubiquitination and proteasomal degradation 
of p53 include the lysines that are required 
for neddylation. This evidence demonstrates a 
central role for Mdm2 in p53 neddylation and 
highlighted Mdm2 as an E3 NEDD8 ligase 
for the first time [73]. Mdm2 also neddylates 
Hu antigen R (HuR), a central RNA-binding 
protein regulating cell dedifferentiation, pro-
liferation and survival. In proliferative hepa-
tocarcinoma, colon cancer cells and biopsies, 
HuR is overexpressed due to Mdm2-mediated 
neddylation, stabilizing HuR and protecting it 
from degradation [74]. NF-kB, a critical player 
in cell survival and proliferation, is controlled 
indirectly via neddylation. Overexpression of 
TRIM40 (a RING finger domain-containing 
protein) results in neddylation of IKKg and 
inhibition of NF-kB activity, thereby implicat-
ing NEDD8 conjugation of IKKg as a negative 
regulator for NF-kB activity [75]. Neddylation 
is required for efficient SCFb-TrCP-mediated 
ubiquitination and processing of p105 follow-
ing phosphorylation of the molecule by IKKb. 
p105 is a precursor of one of the subunits in 
NF-kB and thus neddylation adds another 
level of regulation to the NF-kB pathway, via 
IKKb and IKKg [76]. Table 1 summarizes the 
substrates of neddylation involved in various 
types of cancers.
Therapeutic approaches targeting 
neddylation
Targeting proteins involved in protein degrada-
tion appears to be an excellent option for cancer 
therapy. As mentioned before, bortezomib was 
the first commercially available drug directly tar-
geting ubiquitination by inhibiting the action of 
the 26S proteosome. However, given that ubiq-
uitination has a wide range of substrate targets, 
it is not surprising that bortezomib has some 
side effects. The answer may rely on targeting 
 neddylation specifically.
MLN4924 is a small molecule inhibitor of 
NAE, discovered in 2009, that has been shown 
to be very effective, without the undesired side 
effects seen in bortezomib [77,78]. NAE catalyzes 
the formation of a covalent NEDD8-inhibitor 
adduct with MLN4924. By blocking NAE, the 
turnover of CRL substrates is completely dis-
rupted and leads to the activation of apoptosis 
as a consequence of the deregulation of S-phase 
DNA synthesis. In vivo tests demonstrated that 
MLN4924 suppresses the growth of human 
tumor xenografts at doses that are well tolerated 
without any serious toxicity problems. In mouse 
models, a single dose of MLN4924, at 10, 30 or 
60 mg/kg, was shown to reduce NEDD8–cullin 
levels after 30 min in a similar manner across all 
three concentrations. In vitro studies also dem-
onstrated that MLN4924 treatment inhibited 
overall protein turnover by approximately 9% 
(p = 0.023) 4-h post-treatment, while bortezo-
mib inhibited protein turnover by approximately 
50% (p < 0.001) [77,78]. In acute myeloid leuke-
mia mouse models, the generation of reactive 
oxygen species was shown to be a major con-
tributor to MLN4924-induced apoptosis. In this 
study, MLN4924 led to a significant regression 
Table 1. Relevance of neddylation substrates in different types of cancer.
Type of cancer Neddylation substrate Substrate function Ref.
Renal VHL E3-ubiquitin ligase activity, tumor suppressor gene [65,66] 
High-grade neuroendocrine lung 
tumors
Cul-1 Degradation of proteins that regulate cell cycle 
progression
[67] 
Squamous cell carcinomas SCCRO, also known as DCUN1D1 Forms part of the E3 ligase complex for neddylation [68,69] 
Liver and colon Hu antigen R RNA-binding protein regulating cell de-differentiation, 
proliferation and survival
[74] 
Gastrointestinal IKKg Leads to activation of NF-kB [75] 
Various types of cancer Mdm2 Promotes neddylation of p53 [73] 
Various types of cancer Cul-1 component of SCFb-TrCP Processes p105, the inactive precursor of a subunit of 
NF-kB
[76] 
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Executive summary
Background
n Ubiquitination regulates intracellular protein levels and is essential for many cellular processes including the cell cycle and the regulation 
of gene expression.
Targets for the ubiquitin-dependent mechanisms in cancer
n Several malignancies and certain oncogenic viral infections are characterized by alterations of the ubiquitin–proteasome pathway.
n The deregulation of many E3 ligases, such as MDM2, BRCA1 and Smurf2, has been implicated in many cancers.
Therapeutic approaches for inhibition of ubiquitination in cancer
n Bortezomib was the first anticancer drug inhibiting the 26S proteasome.
n Other proteasome inhibitors with improved properties are currently under clinical investigation, such as carfilzomib and marizomib.
The role of neddylation in cancer
n Neddylation regulates the protein degradation pathway. The most widely studied class of protein substrates of neddylation are the 
cullin-RING ligases.
n The deneddylation of cullins is carried out by the COP9 signalosome and DEN1, also known as Nedd8-specific protease.
Targets for neddylation in cancer
n Substrates of neddylation and molecules involved in the process, for example VHL, CAND1 and SCCRO, have been implicated in  
various cancers.
Therapeutic approaches targeting neddylation
n MLN4924 is a small molecule inhibitor of the neddylation-activating enzyme and exerts effects via induction of apoptosis and 
irreversible senescence. MLN4924 in conjunction with already established radiation therapy treatments shows a synergistic effect.
Conclusion
n Neddylation may serve as a potential target in novel and promising cancer therapeutic strategies.
of disease and inhibition of neddylated cullins 
[79]. In preclinical models of activated B-cell-like 
diffuse large B-cell lymphoma, treatment with 
MLN4924 resulted in potent NF-kB pathway 
inhibition. In vivo studies in mice bearing human 
xenograft tumors of activated B-cell-like and ger-
minal-center B-cell-like diffuse large B-cell lym-
phoma blocked NAE pathway biomarkers and 
resulted in complete tumor growth inhibition [80].
Apoptosis does not seem to be the only route 
by which MLN4924 exerts its effects. In vari-
ous human cancer cell lines, MLN4924 treat-
ment induced irreversible senescence independent 
of pRB/p16 and p53, but dependent on p21, a 
mediator of senescence and a known substrate of 
CRL/SCF E3s. MLN4924 action therefore seems 
to be two-pronged via induction of apoptosis and 
irreversible senescence [81].
Recent studies have focused on using 
MLN4924 as a radiosensitizer for the treat-
ment of pancreatic cancer in mouse models 
and otherwise resistant leukemia cell lines. By 
using MLN4924 in conjunction with already 
established radiation therapy treatments, these 
studies demonstrated the synergistic effect 
of MLN4924 with other chemotherapeutics 
[82,83]. The success of MLN4924 in these pre-
liminary studies is encouraging and highlights 
the importance of designing other neddylation 
pathway inhibitors that could prove to be novel 
chemotherapeutic agents in the future.
Conclusion
Neddylation and ubiquitination have been 
shown to regulate several molecules involved 
in crucial steps of tumorigenesis. Our current 
understanding of the mechanism of action of 
the neddylation process supports the notion 
that inhibition of this pathway is a novel and 
promising cancer therapeutic strategy. A good 
example is the development of MLN4924, a 
NAE small molecule inhibitor. MLN4924 
actions alter the function of vital tumor sup-
pressors and oncogenes and led to encouraging 
results in preclinical trials as a monotherapy or 
in combination with other chemotherapeutic 
agents.
Future perspective
Inhibition of ubiquitination as a new entry point 
for cancer therapy has been under investiga-
tion for many years. Bortezomib has demon-
strated certain cancer cell selectivity but also 
some cytotoxicity as ubiquitination has a wide 
range of substrate targets. Inhibition of the ned-
dylation pathway is an underexplored therapeu-
tic approach in cancer and it may be a key new 
candidate for targeted therapy. Our knowledge 
of the importance of the neddylation pathway 
obtained over the past decade indicates that 
selective disruption of the neddylation conju-
gation process may be an innovative and unique 
approach to fight cancer that could be less 
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associated with toxicity. Future work, resulting 
in a better understanding of this pathway and 
how it specifically interferes with development 
and progression of cancer regulation, will pro-
vide additional entry points to selectively impede 
NEDD8 function and is clearly worth explor-
ing. Furthermore, the development of specific ned-
dylation inhibitors that could be applied alone or 
in combination with other therapeutic agents in 
clinical trials might lay down the foundation for a 
more effective cancer treatment.
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